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INTRODUCTION 
Breast carcinoma is one of the most common non-skin 
malignancies and is the leading cause of death in women, comprising 
about 22.9% of all cancers in woman worldwide1. However, non-
cancerous conditions of the breast are far more common than carcinomas. 
The breasts are composed of specialized epithelium and stroma that gives 
rise to both benign and malignant neoplasm. The incidence of female 
breast cancer is rising rapidly between the age group of 35 to 50 years 
worldwide. Invasive ductal carcinoma comprises the largest group of 
malignancy constituting about 65% - 80% of all breast carcinomas2. 
The advent of the medical science has conquered many of the 
infectious diseases that formerly destroyed large populations of the 
mankind, but cancer still remains as an unconquerable disease of the non-
epidemic kind. It’s ironic and tragic that lesions arising from the breast, 
readily accessible to self-examination and clinical diagnosis, continue to 
take a heavy toll on the female gender. Clinical examination, 
mammographic imaging studies and fine needle aspiration cytology have 
traditionally been used as a triple assessment tool for evaluation and 
diagnosis of the breast lesions2. 
Two cytological methods that have been used to obtain material 
from breast lesions are aspiration of secretions from the nipple and Fine 
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Needle Aspiration Cytology of breast lesions. Aspiration cytology of 
nipple secretions is only of a limited use, whereas the application of fine 
needle aspiration undoubtedly has a major influence on the evaluation 
and diagnosis of the breast lesions2. 
Fine needle aspiration offers a rapid and safe diagnostic approach 
which is usually being employed as an outpatient procedure without any 
need for anaesthesia. In the experienced hands this technique is highly 
reliable and promptness of diagnosis alleviates patient anxiety and allows 
time to plan for definitive management. The average sensitivity of this 
procedure is about 87%, the specificity and positive predictive values are 
nearly close to 100%, while the negative predictive value still hovers 
around 60%2. 
Even then the lesions of the breast pose various diagnostic 
difficulties in distinguishing benign from malignant lesions. Since most 
of the malignant neoplasm show increased proliferative activity, research 
had been directed towards finding a reliable proliferative marker. Mitotic 
index forms one of the oldest and reliable proliferation markers since the 
advent of light microscopy, but its reproducibility has been greatly 
debated3. Since then various such markers has been identified. Nucleolar 
Organizer Regions (NOR’s) forms one of the earliest proliferation marker 
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discovered and utilised by Ploton et al. in 1986 to distinguish benign from 
malignant neoplasm, the latter showing more abundant NORs4. 
The AgNOR staining is quiet simple and easily affordable 
compared to other expensive and complex procedures like enumeration of 
S phase fraction (SPF), Proliferating Cell Nuclear Antigen (PCNA), Ki - 
67 index and MIB – 1 index. “Earlier the diagnosis of the lesion better is 
the prognosis”. Having this concept in our mind, our present study has 
been conducted to assess the accuracy of AgNOR as a proliferation 
marker in differentiating benign and malignant epithelial breast lesions on 
Fine Needle Aspiration Cytology. 
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AIMS AND OBJECTIVES 
1) To assess the value of AgNORs in differentiating benign from 
malignant neoplasm of breast. 
2) To evaluate the ability of AgNOR score in differentiating benign 
proliferative lesions from non-proliferative lesions of breast. 
3) To correlate the value of AgNOR score with Robinson’s cytological 
scoring system with regard to malignant lesions of the breast. 
4) To evaluate the usefulness of AgNORs as a proliferation marker and a 
prognostic indicator of neoplastic cells. 
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REVIEW OF LITERATURE 
The human female breasts are modified sweat glands forming a 
conical projection between the subcutaneous tissues and the pectoral 
muscles. The upper outer quadrant contains about 40 to 50% of mammary 
tissue5. The mammary tissue is divided into 10-15 ill-defined lobes, 
which are pyramidal in shape with its apex at the areola. The glandular 
tissue of each lobes drain into the single collecting duct forming 
subareolar dilatation known as the lactiferous sinuses before emerging at 
the nipple. Along the length of these ducts arise the lobular units 
embedded in a loose connective tissue stroma. Both the glandular and the 
stromal component give rise to a variety of benign and malignant 
neoplasm of breast (Fig 1). Both the ducts and the lobular units are lined 
by a single layer of cuboidal to columnar epithelium surrounded by a 
basket weave array of myoepithelial cells. Lymphatic drainage of the 
breast tissue lateral to the nipple is towards the axillary group of nodes 
while those breast tissues medial to that of the nipple is towards the 
internal mammary group of nodes5. 
There is no discernible variation between the male and female 
breast tissues from the time of conception until puberty. While at puberty 
females exhibit branching and further lengthening of their ducts 
accompanied by lobular development and proliferation of fibrous stroma 
 and fat tissues reaching their maximum breast development by the age of 
20 years6,7. The menstrual cycle is accompanied by m
the breast tissue, but major physiological changes
seen during pregnancy and lactation. 
breast tissue during menopause which merges with aging associated 
atrophy of the breast. 
FIGURE 1 Anatomic
These physiological changes at the various age groups give
radically different histological appearances
differentiated and compared with the
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BENIGN EPITHELIAL LESIONS 
 A wide variety of benign lesions arising from both the ducts and 
lobules have been observed in the breast. These include non-proliferative 
changes, proliferative breast lesions and proliferative breast diseases with 
atypia. 
NON-PROLIFERATIVE CHANGES 
 This group includes wide variety of lesions including duct ectasia, 
simple cysts of breast, apocrine metaplasia, fibrosis and adenosis of the 
breast. All these are grouped under the term fibrocystic changes of breast. 
These lesions generally show fragments of usual duct epithelial cells with 
a background composed of cyst fluid and cyst macrophages along with 
scattered bare bipolar nuclei.  
CYSTS OF THE BREAST 
 Single or multiple cysts of various sizes are the most common 
cause of palpable breast swelling. Cysts are the manifestation of 
fibrocystic disease and are lined by a single layer of cuboidal or flattened 
epithelium, occasionally forming papillary projections. The lumens of the 
cysts are filled with fluid, usually containing desquamated cells and large 
cells with vacuolated cytoplasm, known as foam cells (cyst 
macrophages)9. 
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 The fluid from breast cysts are fairly rich in vacuolated 
mononuclear or multinuclear “foam cells” of various sizes, and contains 
various numbers of benign duct epithelial cells that are often poorly 
preserved. In cysts with papillary proliferation, the epithelial cells are 
usually more abundant and larger. Approximately one-third of breast 
cysts are lined by large cells, referred to as apocrine metaplasia cells 
which contain numerous coarse granules which impart an eosinophilic 
appearance to the cytoplasm. 
FIBROCYSTIC DISEASE 
Fibrocystic disease is the commonest disorder of the female breast. 
It occurs in the mature woman, particularly in the pre-menopausal years. 
It simultaneously involves the ductal, lobular and stromal elements of the 
breast. The disorder is also variously referred to as cystic mammary 
dysplasia, benign mammary dysplasia, fibroadenosis, and benign cystic 
mastopathy. The affected ducts show areas of dilatation (duct ectasia), 
which may appear as cyst containing fluid (cyst formation). The lobular 
ductules undergo hyperplastic proliferation (adenosis) and are surrounded 
by proliferating stroma (fibrosis). In one variant of fibroadenosis, the 
hyperplastic ductules are separated and compressed into tubular shapes 
by bands of dense fibrous tissue (sclerosing adenosis)10. Hypertrophy and 
multiplication of the lining epithelium may also occur (epitheliosis). The 
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key features to its diagnosis include usually scanty cohesive sheets of 
benign duct epithelial cells forming a honeycomb pattern with variable 
number of benign apocrine cells and foam cells in the background of 
scattered naked bipolar nuclei11. Necrotic material may be present in 
cases with marked dilatation of ducts and the foamy macrophages show 
inspissated secretions with dark-staining nuclei and a “dirty” appearance 
of the cytoplasm12. 
The cellular presentation of fibrocystic disease is variable. Dense 
fibrous tissue is resistant to aspiration and when fibrosis is the 
predominant component, the sample may be virtually acellular. In cases 
of marked adenosis, the smear may show only epithelial cells. The 
cytological diagnosis is therefore necessarily incomplete and as such 
fibrocystic change is not a specific cytological diagnosis. Wellings and 
Alpers13 stated that patients in the age group of 13 to 19 years showed no 
apocrine metaplasia whereas this change was identified in over half of 
those above 30 years. 
PROLIFERATIVE BREAST LESIONS 
 These are again subdivided into two groups proliferative breast 
diseases without / with atypia. Under the category of proliferative disease 
without atypia comes the moderate to florid epithelial hyperplasia 
(epitheliosis), complex sclerosing lesion (radial scar), papilloma, 
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sclerosing adenosis. While under the category of proliferative disease 
with atypia comes the atypical ductal / lobular hyperplasia. 
EPITHELIAL HYPERPLASIA 
 Normally the ducts and lobules are lined by double layer of 
epithelial and myoepithelial cells. The epithelial hyperplasia is defined as 
the presence of more than two layers of cells which can be from either 
luminal or myoepithelial cell type and these hyperplastic cells tend to 
distend and occlude the lobules and ducts and even cause distortion of 
their shape resulting in formation of irregular lumens. 
 Cytology wise, they are cellular smears with large slightly 
disorganised sheets of cohesive duct epithelial cells with a tendency of 
these cells to be arranged in a ‘streaming’ pattern with focal crowding 
and overlapping of the nuclei, with mild or absent nuclear atypia in a 
background of few scattered bare bipolar nuclei and a few foamy cells14. 
ATYPICAL DUCTAL HYPERPLASIA: 
 Atypical ductal hyperplasia has a high cellular proliferation 
resembling that of low-grade ductal carcinoma in situ and there is a 
considerable overlap between these two entities and there is no single 
feature that can be confidently used to differentiate between them15. 
 Cytology wise, they are highly cellular smears with large sheets of 
cohesive mildly atypical epithelial cells with many holes indicating a 
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cribriform pattern with occasional naked bipolar and myoepithelial nuclei 
in a background showing necrotic debris and calcium granules. 
DUCT PAPILLOMA 
 These are a group of breast neoplasm that may cause significant 
diagnostic problems. The main secretory ducts are the most common sites 
of these neoplasm and they usually present with bloody nipple discharge. 
The epithelium lining a cystically dilated duct hypertrophies and forms 
papillary ingrowths into the cyst cavity which are seen as complex 
branching epithelial sheets and finger like projections lined by epithelial 
cells showing mild nuclear atypia with a dense fibrovascular stromal core 
and are seen along with macrophages and variable amount of cystic fluid 
in a background showing sparse naked bipolar nuclei16. Benign duct 
papillomas may be single or even multiple in number17. 
INVASIVE DUCTAL CARCINOMA 
Galen in 2nd century A.D described breast cancer as “The breast 
carcinoma exactly resembles the animal crab. In this disease, the veins 
extending out from the unnatural growth take the shape of a crab’s legs18” 
Rosen19 (1979) stated that invasive ductal carcinoma accounted for 75% 
of breast cancer deaths. Current opinion is that the Terminal Duct Lobular 
Unit (TDLU) is the site of origin of both invasive ductal as well as 
lobular carcinoma. 
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Azzopardi20 stressed the work of Wellings and colleagues on the 
point of view that most ductal carcinoma arises in the TDLU. Most 
malignant tumours of the breast arising from ductal or lobular epithelium 
are adenocarcinomas. The greater majority by far are invasive ductal 
carcinomas (80%). Invasive ductal carcinoma of No Special Type (NST) 
constitutes the majority of about 75%21. 
 Cytology wise they are highly cellular with neoplastic cells being 
arranged in irregular dyscohesive aggregates or sheets with large 
pleomorphic cells with malignant nuclear features in a background of 
nuclear debris and granular calcium22. 
 The other special categories of primary breast carcinoma include 
lobular carcinoma, mucinous carcinoma, tubular carcinoma, medullary 
carcinoma, papillary carcinoma, clear cell carcinoma, secretory 
carcinoma, adenoid cystic carcinoma and metaplastic carcinoma. 
FINE NEEDLE ASPIRATION CYTOLOGY 
Era of modern diagnostic Fine Needle Aspiration Cytology 
(FNAC), which has now become an integral part of the pre-operative 
diagnosis of any accessible lesions, began with the works and 
publications of G. Papanicolaou and H. Traut in the early 1940’s on 
cytopathological diagnosis of uterine carcinomas23. Diagnostic cytology 
had resurgence in Europe and particularly in Scandinavian countries 
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during the 1950s and 1960s, where it thrived before spreading all over the 
world24. However, histopathological basis for interpretation of cytology 
samples were established only around 1960 by Koss25. In a study 
conducted by Russ about one in eight breast carcinomas diagnosed with 
FNAC were initially considered to be benign lesions on clinical 
examination26. 
In 1986 Grant27 studied from the summary of 18 reported cases the 
following statistics regarding FNA biopsy  
Specificity     - 99.8% 
Sensitivity     - 92.5% 
Accuracy     - 96.5% 
Positive predictive value   - 99.7% 
Negative predictive value  - 94.2% 
In a study done by Kaninsky28 (1984) demonstrated that FNAC 
was an excellent, cost effective diagnostic modality and it may reduce the 
cost of diagnosis by as much as 90% compared with excisional biopsy 
and its requirement for hospitalization. 
FNAC was initially conceived as a means to confirm the clinically 
suspicious diagnosis without subjecting the patient to unnecessary 
surgical interventions29. As a preoperative diagnosis it has several 
advantages by relieving patient anxiety through its rapid diagnosis, 
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offering time for planning in advance for definitive treatment and also in 
preoperative staging of the cancers. 
NATIONAL CANCER INSTITUTE (NCI) – GUIDELINES30 
The NCI has given guidelines for a uniform approach to breast 
FNA biopsy. It recommends the use of 22-25G needle with the needle 
being aimed at the centre of the lesion and moved in different directions 
within the lesion. For necrotic, partly cystic and fibrotic lesions the 
needle should be aimed at the rim of the lesion and sampling should be 
done just within the rim tangentially. Small lesions are better stabilized 
by bringing it to an immobile position under the skin before sampling. An 
average number of 2-4 needle passes is recommended for adequate 
sampling. However more passes are required when encountered with 
following conditions like when the tumour is difficult to stabilize or 
penetrate, a dry tap, larger tumour of more than 4cms. 
Adequacy: Adequacy is assessed by two judgments: First is the 
opinion of the aspirator that the report of the cytological findings were 
consistent with the clinical findings, second is the pathologist opinion that 
the cytology smears do not have any significant artefacts or distortion. 
There are no specific requirements for minimal number of duct 
epithelial cells to be present for adequate sampling. The NCI guideline 
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also recommends the usage of Robinson’s grading system for grading of 
the breast carcinomas. 
CYTOLOGICAL GRADING - ROBINSON’S GRADING SYSTEM: 
Robinson et al31 developed a protocol in 1991 for the cytological 
grading of invasive ductal carcinoma - Not Otherwise Specified (NOS). 
This method has three cytological grades which correlated well with the 
histological grading (Bloom and Richardson histological grading system). 
This method is simple, quick and easily reproducible method. In the 
Robinson’s system of grading for carcinomas of breast, six different 
cytological parameters were applied, namely cell dissociation, uniformity 
of the cell, cell size, nucleolus, nuclear margin and nuclear chromatin. A 
score of 1-3 is given to each one of these parameters and the tumour is 
graded by adding up all the individual scores32. 
Robinson et al. established three cytological grades namely grade I, 
grade II and grade III as depicted in table 1. 
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TABLE 1 ROBINSON’S GRADING SYSTEM31,32 
Criteria Score 
1 2 3 
Cell 
dissociation 
Mostly in 
clusters 
Mixture of 
single 
cells and cells in 
clusters 
Mostly single 
cell 
Cell uniformity Monomorphic Mildly 
pleomorphic 
Pleomorphic 
Cell size 1-2 times RBC 
size 
3-4 times RBC 
size 
>5 times RBC 
size 
Nuclear margin 
 
Smooth Folds Buds and clefts 
Nucleoli 
 
Indistinct Noticeable Abnormal 
Chromatin Vesicular Granular Clumped and 
cleared 
Final score ranges from 6 – 18 and these were graded below as 
Grade I : Score 06 – 11 
Grade II : Score 12 - 14 
Grade III : Score 15 - 18 
The accuracy of Robinson’s grading method was 83%, true 
positivity was 77.33% and false negativity was 11.33%33. 
Mouriquand J et al.34 applied a cytological grading method for 
FNAC smears of breast. Both Topographic and Nuclear Criteria were 
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given more importance in this method. Three grades of classification of 
tumours were followed. The salient features of grading system were 
TABLE 2 GRADING SYSTEM OF MOURIQUAND et al 
Criteria Grade 1 Grade 2 Grade 3a Grade 3b 
Cells In clusters Both clusters 
and isolated 
cells 
Predominantly isolated cells 
Shape & 
size  
Uniform Larger Anisonucleosis 
Chromatin Regularly 
distributed 
Irregularly 
distributed 
Highly dispersed 
Cytoplasm - - Absent Well preserved 
Nucleoli - Enlarged blue Bright red Bright red with a 
surrounding 
clear halo 
Mitosis - - - Numerous  
 
This Mouriquand’s grading method has an accuracy of 77%, true 
positivity of 69.33% and false negativity of 15.33%33. Mouriquand’s 
grading method34 also corresponded well with that of the Bloom and 
Richardson grading system and had a good positive prognostic 
correlation. However, this method had not gained wide acceptance. In a 
study comparing the two methods with that of histological grading35, the 
diagnostic accuracy and sensitivity of both Robinson’s and Mouriquand’s 
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methods were similar. However, Mouriquand’s method had a low 
specificity. 
The Robinson’s method of cytological grading was far more 
specific when Bloom and Richardson method of histological grading was 
considered as gold standard. The criteria for grading32 tumour by the 
Robinson’s grading system were simpler and easier to reproduce as 
compared to the Mouriquand’s grading system. The other grading 
systems of importance are Hunt’s et al grading system which has an 
accuracy of 70.66%, true positivity of 70.66% and false negativity of 
29.33% and the Howell (SBR) Grading System which has an accuracy of 
53.89%, true positivity of 40% and false negativity of 31.25%. 
 Compared with other cytological grading systems Robinson’s 
grading system had a correlation of about 83% with Bloom and 
Richardson histological grading method and the sensitivity and specificity 
were highest by Robinson’s cytological grading system. The Robinson’s 
method of cytological grading was also far more specific when Bloom 
and Richardson histological grading method was considered as gold 
standard32. 
Dutta et al36 (2001) studied fine needle aspiration cytology of 51 
cases of breast masses out of which  28 turned out to be malignant and 
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the remaining were benign lesions composed of fibrocystic disease, 
mastitis and fibroadenoma. Diagnostic accuracy of FNAC was 90.2%. 
Chaiwum et al37 (2002) studied  Fine Needle Aspiration Cytology 
of 2375 cases from 1994 to 1999, benign lesions accounted for 48%, 5% 
were suspicious for malignancy, malignant neoplasm accounted for 15%, 
32% were unsatisfactory smears. FNAC showed a specificity of 99.5% 
and sensitivity of 84.4%. 
Young et al38 (2002) reported that aspiration cytology of 
carcinomas of the breast were rightly identified as malignant and the 
values of each of the subtypes were - ductal carcinoma - 65%, for lobular 
carcinoma it was 20%, for mucinous variety it was 27% and for 
medullary carcinoma it was 12%. This study showed that Fine Needle 
Aspiration Cytology is the most reliable method for breast carcinoma 
diagnosis. 
HISTOLOGICAL GRADE 
 Bloom and Richardson histological grading method is the most 
widely used method for grading of the breast carcinoma and this method 
is easily reproducible, quite simpler and gives good positive prognostic 
implications. This system grades breast carcinoma into three histological 
types based on measurement of tubular differentiation, nuclear 
pleomorphism and proliferative activity (mitotic figures)39. 
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TABLE 3 BLOOM AND RICHARDSON HISTOLOGICAL 
GRADING SYSTEM39 
Parameter Criteria Score 
 
Tubule Formation 
> 75% 1 
10-75% 2 
< 10% 3 
 
Nuclear Pleomorphism 
Small and uniform 1 
Moderate variation 2 
Marked variation 3 
 
Mitotic count / 10hpf 
0 - 5 1 
6 - 10 2 
>11 3 
 
 The breast carcinomas were graded into 3 grades after summing up 
all the score of the three features and values range from 3 – 9. 
TABLE 4 BLOOM AND RICHARDSON HISTOLOGICAL 
GRADING SYSTEM39 
Grades Score 
Grade 1 (well differentiated) 3 – 5 
Grade 2 (moderately differentiated) 6 – 7 
Grade 3 (poorly differentiated) 8 – 9 
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AgNORs: ARGYROPHILIC NUCLEOLAR ORGANIZER REGIONS 
The Nucleolar Organizer Regions (NORs) are loops of DNA 
projecting into the nucleoli of interphase nuclei40. These are specific 
portions of DNA (deoxyribonucleic acid) called rDNA (ribosomal DNA) 
that, by using the enzyme RNA (ribonucleic acid) polymerase-1, codes 
for the transcription of ribosomal RNA (rRNA) which in turn results in 
the synthesis of proteins by the cell. Since NORs encode for ribosomal 
RNA a necessary step in protein synthesis (Fig 2), it has been suggested 
that they correlate with cellular proliferative activity41. Organization of a 
typical Nucleolar Organizer Region (NOR) is shown in figure 2. 
Nucleolar Organizer Region (NOR) are DNA loops that are located 
at the ends of each of the acrocentric chromosomes 13, 14, 15, 21 and 
2240. NORs occur in pairs on the five acrocentric chromosomes (one on 
each of the daughter chromatid), and at the metaphase potentially 20 
NORs could be seen. However, in diploid cells visualising ten NORs can 
be regarded as a full complement, as the metaphase is a very transient 
phase. 
 FIGURE 2 Organization of a 
PHYSIOLOGY OF AgNOR’S AND CELLULAR KINETICS:
Ultra structure of the human
These are composed of
1. The dense fibrillar component 
2. The fibrillar center
3. The granular component.
The dense fibrillar component 
dense 3-5nm thick fibrils and is
precursors and stains with antibodies
protein associated with U3 small nuclear ribonucleoprotein (SnRNP)
The fibrillar center is 
and it contains topoisomerase I, RNA polymerase I and ribosomal DNA
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It is equivalent to that of interphase NOR visualised by the light 
microscopy. 
The granular component is composed of particles of ribosome 
precursor. 
Tumour behaviour mainly depends upon the Cellular kinetics. The 
behaviour of the tumour can be assessed by determining the proliferation 
rate. The cell cycle can be divided into four phases based on the nuclear 
chromatin activity. They are S, G1, G2 and G0 phases. There is a short 
resting phase of the cell undergoing replication at the ‘S’ phase. Thus, the 
DNA content at the end of ‘S’ phase is an indicator of proliferative 
activity and AgNOR detects the DNA content at this stage43. 
The size, shape and number of the NORs vary according to 
nucleolar transcription and are related intimately to the cell cycle. Since 
nucleolar transcription rate and cell turnover is comparatively high in 
proliferating cells, assessment of the morphology and quantity of NORs 
helps in assessing cell proliferation. 
During the prophase there is dispersion of the components of the 
fibrillar centre and these structures exist in a constant position at 
metaphase which are seen on the short arms of five acrocentric 
chromosomes - 13, 14, 15, 21 and 2240. 
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However, the five acrocentric chromosomes have a tendency to 
associate through the satellite regions of these chromosomes and thus 
have a greater impact on the number of NORs observed and counted. 
DEMONSTRATION OF AgNORs: 
The NORs can be visualised by various techniques which either 
demonstrate NOR associated proteins or the ribosomal DNA itself 
TABLE 5 DEMONSTRATION OF NORs41 
Reagent Target 
Silver colloid (AgNOR) NORAPs 
Bismuth ions 100K NORAP 
Radiolabelled rRNA rDNA 
Antibodies NORAP epitopes 
The most popular and the simpler method among all these in 
identifying the NORs is the silver staining technique. The structures 
demonstrated by this method are called AgNORs (Argyrophilic Nucleolar 
Organizer Regions). This silver staining technique identifies neither the 
rRNA nor the rDNA, but the acidic NORAPs (Nucleolar Organizer 
Region Associated Proteins) seen in association with the site of RNA 
transcription. 
AgNORs are usually aggregated tightly within one or two nucleoli 
in a normal cell, as seen in cytological smears and individual AgNORs 
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are often not discernible. The number of AgNORs detected depends upon 
several of these factors44. These include- 
1. The stage of the cell cycle.  
2. The number of NORs bearing acrocentric chromosomes in their 
karyotype 
3. The level of transcriptional activity of the cell. 
There is thus a remarkable difference between AgNOR counts in 
chromosome spreads and those observed in histology sections of the 
similar cell preparations. Since the AgNORs congregate within a 
relatively small nucleolus in histological sections, there is a greater 
difficulty in visualising the individual AgNORs. 
In malignant lesions, the AgNORs are dispersed throughout the 
nucleus to a varying extent, enabling them to be easily visualised by the 
cytologists. Therefore quantification of the AgNORs in interphase nuclei 
is probably related more to their dispersion throughout the nucleoplasm 
than to the actual number present in the nucleus. Therefore ‘AgNOR 
count’ in benign and malignant lesions does not denote the absolute 
number of AgNORs but it is rather a numerical index of dispersion of 
AgNORs within the nucleus. This connotes that dispersion in itself may 
reflect the proliferative state of the cell. Hence the number of visible 
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AgNORs indicates the number of cells in the current phase of 
transcription43. 
NORs were first visualized in 1975 by means of a simple silver 
staining technique that recognizes these argyrophilia-associated proteins 
where they appear as black / brown dots within the nucleus of the cell. 
The claims that AgNORs were visualised significantly higher 
within the nucleus of malignant tumours compared to that of the reactive / 
benign lesions has attracted a lot of attention for AgNORs being regarded 
as a cell proliferation marker43. 
An apparent increase in the mean AgNOR count was noticed in the 
cells under the following conditions: 
1. When the cell proliferation was very active, the nucleolar 
dissociation was present in almost all cells, and that the AgNORs 
were seen throughout the nucleus. 
2. A defect of the nuclear association could result in AgNOR 
dispersion throughout the nucleus. 
3. An increase of the AgNOR bearing chromosomes resulting from 
increased cellular ploidy. 
4. Prominent increase in AgNOR activity is associated with increased 
transcriptional activity. 
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In the benign neoplastic cells AgNORs are aggregated within a 
relatively condensed small nucleus and hence show only 1-2 AgNOR per 
nucleus, which is been attributed to the difficulty in visualising the 
individual NORs. While in malignancy, or in conditions of increased 
cellular proliferation, AgNORs get dispersed throughout the nucleus, 
enabling the cytologist to enumerate them more easily. Hence, the 
AgNOR quantification depends mainly on the degree of disaggregation or 
dispersion of large number of AgNORs within the nucleus of the 
neoplastic cells. 
AgNOR – TECHNICAL ASPECTS 
The main advantage of the AgNOR staining technique is that, it is 
a one-step silver-staining method, which is a relatively simpler staining 
method, and also has the advantage of the ease of application of this 
staining method even onto the archival tissues.  It can also be used to 
demonstrate NORs easily on routinely processed cytology smears and 
histology sections45. The principle disadvantage is the time consuming 
process of counting of the little dots, often associated with inter-observer 
variations. 
In concise form, the one step silver-staining method consist of a 
mixture of 50% silver nitrate solution and 1% formic acid in 2gms% of 
gelatin solution which acts as a colloid stabilizer41. These solutions have 
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to be prepared separately and mixed freshly upon use. Cytological smears 
are incubated in this solution mixture for a period of 45 min to one hour 
and then washed, dehydrated, cleared and mounted for light microscopy 
examination. Both the light microscopy and ultra structure studies have 
implicated that this method is remarkably specific as a means of detecting 
interphase / metaphase NORs. Staining sequentially with radiolabeled 
rDNA and rRNA has shown a good correspondence between the binding 
sites and silver stained NORs in interphase nucleoli and on chromosome 
spread. 
The NORs can be seen as discrete black / brown dots in a pale 
yellow background at the light microscopy level and can be enumerated 
using an oil immersion lens. Counts in 50-100 neoplastic cells are usually 
made and the results are expressed as a mean number of AgNORs 
visualised per nucleus. Lymphocytes are usually employed as internal 
controls. 
This technique can be used with success after making minor 
modifications, in both semiautomatic and automatic image analysis 
hardware46. In this technique the total amount of AgNORs per nucleus is 
measured, rather than the number of sites counted. 
The intensity of the AgNOR staining is observed to be dependent 
on the fixation regimen employed and results vary from one fixative to 
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the other. Alcohol based fixatives, Carnoy’s fixative and 95% ethanol 
gives optimal results. Mercury and dichromate fixatives are highly 
detrimental to the AgNOR staining47. 
AgNOR STAINING REACTION & PROBLEMS: 
 The silver staining technique is based upon the principle that, the 
silver salts as a result of their high electron charge density and by virtue 
of their phosphate moieties have a high affinity for the acidic NORAPs. 
Generally, the AgNOR silver staining method is been run for about 
one hour irrespective of whether cytological smears or histological 
sections were stained, but recently minor alterations have been put forth 
to reduce the staining time and also to incorporate internal controls to 
allow counting of subsidiary AgNOR dots. 
First, the persistent problem with the usage of any kind of silver 
staining method is the non-specific silver grain deposits in the 
background. Usage of clean glassware and very pure deionised water can 
overcome this background staining. However, recently certain minor 
modifications in the AgNOR staining method have been put forth that can 
overcome this problem of background staining. These are: 
1. Usage of an inverted incubation technique, where the slides are 
inverted into the staining solution. This technique helps in maintaining 
a high degree of contrast between the background and the AgNORs48. 
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2. Glycine blocks both free and reversibly bound aldehyde residues left 
over by formalin fixation, thereby reducing the background silver 
precipitation. Hence, pre-incubation with glycine prior to AgNOR 
staining can reduce the background stain. 
3. After completion of the staining procedure immersing the slides in a 
10% nitric acid solution can minimise the background stain. 
4. Replacement of gelatin by polyethylene glycol as a protective 
colloidal developer medium49. 
Second, the intensity of staining varies considerably even with 
slight variations of the staining time; which if over-stained obscures the 
individually clustered AgNORs within nucleoli, or if under-stained 
renders them too faint to be assessed. 
Third, in the histology sections even minor variations in the 
thickness of the sections affect the apparent number of AgNORs within 
the nuclei, thus requiring uniformity in section thickness of around 3 - 4 
µm. Application of this technique to cytology smears thus eliminates this 
problem50. Thus AgNOR dot count study on cytological smears has 
shown to be far more superior compared to those on histological sections. 
Cytological smears also show a better discriminative value of AgNOR 
dots compared to those on histological sections51. 
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One great advantage of this technique is that, previously stained 
cytology slides can also be reused for silver staining, thus providing an 
excellent guide to the diagnosis especially in doubtful cases and when 
extra-unstained slides are not available. 
The major disadvantages are: 
1. Inter-observer variation is the major cause of inaccuracy and 
inconsistency. 
2. The counting procedures adopted are usually manual and are prone to 
subjective variations. 
3. Misjudged counts may result due to overlapping of the NORs within 
the nucleus43. 
4. The dots of AgNOR in the interphase nuclei may not always 
correspond to the number of such types in the karyotype of the 
nucleus52. 
MODIFICATIONS IN THE AgNOR TECHNIQUE: 
After the AgNOR technique was first described by Ploton in 1986 
it has undergone several modifications with an aim to improve the overall 
staining quality. Some of the modifications that are worthwhile to 
mention include 
First, combination of Feulgen reaction with modified AgNOR 
staining technique, which not only enables the counting of active NORs 
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but also the evaluation of the amount of DNA within the same cell 
nucleus by the Feulgen reaction. 
Secondly, combination of AgNOR staining technique with 
cytofluorometric analysis on cell suspensions. 
Thirdly, the use of AgNOR technique along with automatic image 
analysis software makes these technique far less prone to subjective 
errors than the traditional methods46. 
AgNOR - ENUMERATION 53 
The types of Nucleolar Organizer Regions within the nucleus can 
be categorized into three groups. 
The first one is the ‘Aggregated AgNOR’ which are seen as 
rounded, solitary structures and corresponds to the nucleolus of the cell, 
this type is often seen in resting cells and lymphocytes and the individual 
NORs cannot be distinguished within the nucleus of these cells. 
The second type is the ‘Nucleolar pattern’ which is seen in the 
nucleus of the proliferating cells and the NORs are seen to be dispersed 
only within the nucleolus of the cell. 
Finally, the third type is the ‘True AgNORs’ that are seen to be 
dispersed throughout the nucleoplasm and are often seen in highly 
malignant neoplastic cells. These features can be demonstrated well in the 
cytological smears53. 
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METHODOLOGY: 
There are five methods for enumeration of AgNORs based on their count, 
morphology and distribution. They are 
1. Mean AgNOR count 
2. AgNOR proliferative index  
3. AgNOR size variation grading 
4. AgNOR distribution in the nuclei 
5. Subjective AgNOR Pattern Assessment (SAPA) 
Mean AgNOR count (mAgNOR): 
Mean count of the number of NORs present in the nucleus of the 
100 neoplastic cells. mAgNOR value correlates with the mean DNA 
content of the cells indicating the cell ploidy. 
AgNOR proliferative index (pAgNOR): 
It is the percentage of neoplastic cells exhibiting more than five 
NORs within the nucleus of the 100 counted cells. pAgNOR value 
represents the number of cells in the S-phase fraction. 
AgNOR size variation and distribution grading: 
In 1991 – 1992 Ahsan et al utilised the criteria of size variation and 
distribution of AgNORs within the nucleus and demonstrated higher 
variation score of these parameters in malignant neoplasm compared to 
the benign counterparts. 
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TABLE 6 AgNORs SIZE VARIATION GRADING 
AgNOR Size Variation Score 
More or less uniform 0 
Two different sizes 1+ 
More than two different sizes (but not those of 3+) 2+ 
All grades and sizes including too minute to be 
counted 
3+ 
 
TABLE 7 AgNOR DISTRIBUTION IN THE NUCLEI 
AgNOR distribution - nuclei Score 
Limited to nucleoli 0 
Occasional dispersion outside nucleoli 1+ 
Moderate dispersion outside nucleoli 2+ 
Widely dispersed throughout the nucleus 3+ 
 
Subjective AgNOR Pattern Assessment: 
Meehan et al proposed a method for scoring of AgNORs called 
‘Subjective AgNOR Pattern Assessment (SAPA), which was based on 
morphological patterns, variation in the size and shape of the NORs, and 
whether they are aggregated or scattered54. 
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In a study by Dhakhwa R et al55 on 110 breast lumps observed the 
mean AgNOR count in benign breast lesions was 2.63 ± 1.36 while the 
SAPA score was 6.26 ± 1.19. The SAPA score in malignant breast 
lesions was10.05 ± 2.22 and the mean AgNOR count was 8.42 ± 2.53 
When the cut off score for AgNOR count / nucleus is taken as 6 for 
malignant neoplasm of breast, then the diagnostic accuracy is 95.5%, 
specificity is 88.9%, sensitivity is 89.5%; positive predictive value is 
82.2% and the negative predictive value is 98.5%. 
When the cut off value for SAPA score is taken as 8 for malignant 
neoplasm of breast, then the diagnostic accuracy is 85.5%, specificity is 
83.3 %, sensitivity is 89.5%; positive predictive value is 73.9 % and the 
negative predictive value is 93.8% (Table 7a). 
In cases that presented with diagnostic difficulties on FNAC 
subjective pattern assessment and AgNOR counting showed comparable 
accuracy in differentiating malignant from benign lesions. In some cases 
this may give contradictory results and hence more helpful when they are 
considered together. 
 
 
 TABLE 7a: AgNOR COUNT AND SAPA SCORE IN BREAST 
Diagnosis 
Fibrocystic changes 
Fibroadenoma with 
fibrocystic changes 
Intraductal papilloma 
Infiltrating ductal 
carcinoma - NOS 
TABLE 8 SUBJECTIVE AgNOR PATTERN ASSESSMENT
36 
LESIONS55 
Number of 
cases 
AgNOR Count SAPA score
7  2.71+/-1.38 
7  2.86+/-1.21 
1  5 
32  8.31+/-2.6 
 
 
6+/-1.55 
5.86+/-3.8 
7 
9.94+/-2.2 
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SAPA score is a more rapid, reproducible and and less time 
consuming than counting of AgNOR dots55. Both SAPA score and AgNOR 
counts gave similar results on cytology
56
. 
Khanna AK et al56 in his study found SAPA score was most useful 
in differentiating benign neoplasm from malignant neoplasm of breast in 
both the cytology smears and histology specimens. 
AgNOR – ITS APPLICATIONS: 
 AgNOR as a one step silver colloid staining method was used first 
in the prostatic specimens. As the years followed AgNOR staining 
method was performed on a variety of specimens mainly to differentiate 
malignant from benign lesions. In the malignant neoplasm the increasing 
AgNOR count correlated well with the tumour aggressiveness. 
AgNORS IN BREAST: 
Since the time cytogenetic workup studies were performed 
malignant breast lesions showed unusual and ectopic (Nucleolar 
Organizer Regions) NOR patterns, this has lead the pathologist to explore 
the potential of AgNORs in differentiating borderline breast lesions from 
those of the malignant ones57. According to various studies, AgNOR 
values correlated very well with the prognostic indices like axillary 
lymph node status, tumor size, Ki-67 index, MIB-1 index and mitotic 
counts57. 
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CYTOLOGY APPLICATIONS: 
In the recent past, AgNOR has emerged as a wonderful tool in 
assessing the proliferative activity of a given lesion in the cytology 
smears enabling the cytologist to assess the aggressiveness of the 
neoplasm pre-operatively. Main advantage of AgNORs in cytology 
smears is that one need not worry about the section thickness as in 
histology as thicker sections make it difficult to enumerate individual 
AgNOR dots. While in cytology smears even distribution of cells makes 
enumeration of AgNOR dots quite simpler40. 
In the study conducted by Roller E et al58 in 1993 on 56 cases of 
malignant and 20 cases of benign breast neoplasm, he found a clear 
difference between benign and malignant neoplasm of breast, the latter 
showing significantly higher AgNOR counts. 
Reddy GS, Sesikeran B, Bhaskaran CS59 also in the same year 
conducted a study on ten malignant and benign epithelial neoplasm of 
breast, and they concluded that quantitative analysis of AgNORs enables 
one to differentiate benign from malignant lesions. 
A prospective study was conducted by Karmakar T, Radhika S, 
Gupta SK60 in the year 1995 on the cyotological smears of both benign 
and malignant breast lesions encompassing proliferative lesions, 
fibroadenoma, fibrocystic change and ductal carcinoma of breast, found 
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that the mean AgNOR count of 16.63 in malignant neoplasm was much 
higher and statistically significant compared to the mean AgNOR count 
of 6.39 in benign neoplasm. They concluded that a cut-off AgNOR value 
of 11 can reliably be utilised in differentiating benign from malignant 
neoplasm. Whereas a study conducted on assessing the number of 
AgNOR dots in 64 malignant and 31 benign neoplasm of breast on 
cytological smears by Mehrotra A, Chandra T61 concluded by putting 
forth a cut off point of 4 to be reliable indicator to differentiate benign 
from malignant neoplasm of the breast.  
In a study conducted by Simha et al62 in the year 1996 on the 
prognostic value of AgNORs in breast neoplasm showed that the AgNOR 
counts correlated very well with desmoplasia, mitosis and tumour size. 
Higher NOR counts were seen in ER/PR negative neoplasm. 
In a study conducted by Kumar et al63 in the year 1997 assessed the 
AgNOR count of breast carcinomas in the cytology smears of 56 cases 
and found that the AgNOR counts correlated well with stage of the 
cancer, tumour size, lymph node status and recurrence rate of tumour. 
A prospective study was conducted by Hasnan J, Jayaram G40 on 
the cytology smears of 31 cases of benign and 25 cases of malignant 
breast neoplasm with histological correlation in about 26 cases, found 
that mean AgNOR count ranged from 2.55 to 5.0 in benign neoplasm  
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and the range in malignant neoplasm was 5.8 to 17.2. The difference in 
the mean AgNOR count between the benign and malignant lesions was 
statistically significant. None of the cases showed overlap of mean 
AgNOR values in the cytological smears. 
Khanna AK, Kumar M, Ansari MA, Khanna A64 studied both 
cytology and histology of 73 breast lesions which included 27 benign and 
46 malignant neoplasm and assessed the correlation between cytology 
and histology using Subjective AgNOR Pattern Assessment (SAPA) 
score and mean AgNOR dot counts. They concluded that both SAPA 
score and mAgNOR counts were useful in differentiating malignant from 
benign neoplasm in both histology specimens and the cytology smears 
and both gave similar results. Mean AgNOR count of malignant 
neoplasm was 6.94 while in benign neoplasm it was 2.75 in Fine Needle 
Aspiration Cytology. SAPA score of malignant neoplasm was 9.02 and 
5.87 in benign neoplasm. They concluded that Subjective AgNOR Pattern 
Assessment score is more rapid, reproducible and convenient method of 
AgNOR assessment64. 
Meehan SM, Carney DN, Magee H, Dervan PA54 evaluated the 
cytological preparations obtained from surgical specimens for AgNOR 
count, shape, size and clustering. The malignant lesion had a mean 
AgNOR count of 9.52 while benign lesion had mean AgNOR count of 
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4.44, and they concluded that the diagnostic accuracy of combined 
pattern assessment and counting of NORs was 90% in distinguishing 
benign and malignant neoplasm. The median score for benign lesions 
were 7 and for malignant lesions it was 13.  
AgNORs being indicators of cellular proliferative activity 
correlated well with Ki-67 index in a study conducted by Dervan PA, 
Gilmartin LG, Loftus BM, Carney DN65 on 70 cases of malignant breast 
lesions and 27 cases of benign breast lesions. The correlation between Ki-
67 scores and AgNOR counts was highly significant. The view of these 
authors was also shared by Canepa M et al66 who conducted a study on 53 
cases of intra ductal breast carcinoma. 
Kesari AL et al67 evaluated 120 cases of intra ductal breast 
carcinoma and found a good positive correlation between histological 
grading, AgNOR score and PCNA expression. Poorly differentiated 
tumours had a highly elevated AgNOR counts. 
 Our present study was aimed to find out whether there is any 
significant difference in the AgNOR values of benign and malignant 
neoplasm of the breast and also to find out if there is any significant 
change in the AgNOR values between the non-proliferative and 
proliferative benign lesions of the breast. The correlation between the 
Robinson’s scoring system and the AgNOR scoring system was also 
evaluated in malignant neoplasm of the breast. 
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MATERIALS AND METHODS 
This prospective study was conducted in the Cytology Laboratory 
of the Department of Pathology, Tirunelveli Medical College spanning a 
period of about 18 months from May 2011 to October 2012. From 423 
cases of Fine Needle Aspiration Cytology of breast lesions 100 cases of 
breast lesions were randomly selected and examined, which included 40 
cases of carcinomas and 60 cases of proliferative and non-proliferative 
breast lesions. This study was conducted after obtaining clearance from 
the Institutional Ethical Committee. 
FINE NEEDLE ASPIRATION CYTOLOGY 
FNAC was performed on patients who presented with palpable 
breast lesions. 
INCLUSION CRITERIA: 
• All patients presenting with palpable breast lesions. 
EXCLUSION CRITERIA: 
• Patient who refused FNAC procedure. 
• Patients in whom no definable breast mass can be detected 
• Cytological smears with air-drying artefact or improper staining 
METHOD OF COLLECTION: 
After making the patient comfortable the FNAC procedure was 
explained in detail. The FNA procedure was performed as an outpatient 
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procedure without any anaesthesia in the cytology laboratory of our 
department. FNAC was done after disinfecting the skin with alcohol 
scrub and using a 23 gauge needle with 10ml disposable syringe attached 
to the syringe holder. The palpable breast lesion was fixed between the 
thumb and index finger of one hand and with the other hand the needle 
was inserted to the desired depth within the mass. The material was 
aspirated under negative pressure with 3 - 4 short passes in different 
directions. The needle was withdrawn after the negative pressure was 
released, and the material aspirated was expressed on to glass slides, 
smeared and fixed immediately in 95% ethanol. The slides were stained 
subsequently with Hematoxylin and Eosin and AgNOR stain and 
unstained slides were kept for future examination. 
AgNOR staining was performed using a one step silver – colloid 
technique using a mixture composed of 50 % silver nitrate solution and 
2gms% gelatin in 1% Formic acid solution in a ratio of 2:1. These 
solution mixtures are layered over the slides and are kept in a dark room 
for a period of 50 – 60 minutes. These slides are then washed, 
dehydrated, cleared and mounted for examination under the microscope. 
The detailed AgNOR staining procedure is given in Appendix – I. The 
staining protocol for Hematoxylin and Eosin stain is given in                       
Appendix – II. 
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Cytological grading of breast carcinomas was done according to 
the Robinson et al. grading system which is a three-tier grading system, 
dividing carcinomas into grade 1, grade 2 and grade 3. The AgNOR 
enumeration and analysis of all the smears were done and the 
observations were noted down by making a master-chart with all the 
features of the above grading system. Correlations between these grading 
systems were assessed. For this study, an Olympus microscope with 10X, 
40X and 100X magnification objectives and 10X magnification eyepiece 
was used. The digital images of the selected stained smear preparations 
were photographed. 
ENUMERATING AgNORS: 
AgNORs are visualised as blackish or brown dots in a pale yellow 
background, both in the nucleolus and within the nucleoplasm. The 
following AgNOR parameters were calculated. 
 
Mean AgNOR count: 
The number of AgNORs within the nuclei of 100 neoplastic cells is 
calculated using a 100X objective. The mean numbers of NORs per 
nucleus were then calculated and results were expressed as a mean count 
+/- Standard Deviation. 
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Proliferative AgNOR index (pAgNOR): 
 pAgNOR is the percentage of neoplastic cells showing more than 
five AgNOR dots within the nucleus of the 100 counted neoplastic cells. 
 
Distribution and size variation of AgNORs: 
 The size variation and the distribution of the AgNORs within the 
nucleus are evaluated and given a score of 0, 1+, 2+, 3+ according to the 
criteria given in Table 6, Table 7. 
 
Subjective AgNOR Pattern Assessment (SAPA): 
  The SAPA scoring of the AgNORs are done based upon the 
criteria given in Table 8, which takes into consideration the 
morphological characteristics and whether the NORs are clustered or 
scattered within the nucleus. 
 
ROBINSON’S GRADING SYSTEM: 
 Robinsons grading system is used in the grading of malignant 
neoplasm of breast stained with H & E stain. The criterion for this scoring 
system is given in Table 1, which includes cellular dissociation, 
uniformity, size, nuclear margin, nucleoli morphology and chromatin 
pattern. 
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 Correlation study between the Robinson’s score and the AgNOR 
scoring system for grading malignant neoplasm of breast was conducted. 
The ability of AgNORs in distinguishing benign (proliferative and non-
proliferative) neoplasm from malignant neoplasm of the breast was 
studied. 
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OBSERVATION AND RESULTS 
 This prospective study was conducted in the Cytology Laboratory 
of the Department of Pathology, Tirunelveli Medical College for a period 
of 18 months and the following observations were made. 
TABLE 9 BREAST FNAC vs OTHER SITES 
Duration 
Total number 
of FNAC cases 
Number of 
breast FNAC 
cases 
Percentage 
May 2011- 
December 2011 
1622 172 10.6% 
January 2012-
October 2012 
2132 251 11.8% 
Total  3754 423 11.3% 
 
 In the study period of 18 months duration from May 2011 to 
October 2012 Fine Needle Aspiration Cytology was performed on a total 
of 3754 cases. Out of these cases the breast lesions constituted about 423 
cases giving a percentage of 11.3%. 
 172 cases of breast aspiration cytology out of 1622 total aspiration 
cytology cases were studied during the first 6 months period in 2011 
constituting 10.6%. The following 10 month study in 2012 showed 251 
breast aspiration cytology cases out of 2132 aspiration cytology cases 
constituting 11.8%, as shown in Table 9 and Chart 1. 
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TABLE 10 DISTRIBUTION OF NON-NEOPLASTIC AND 
NEOPLASTIC LESIONS ON BREAST CYTOLOGY 
Breast lesions Number of cases Percentage  
Non - neoplastic 32 7.6% 
 
Neoplastic 
Benign 287 67.9% 
Malignant 104 24.5% 
Total  423 100% 
 
Out of the total 423 breast lesions 32 were non-neoplastic 
comprising 7.6% of the total breast lesions. Out of the remaining 391 
neoplastic cases benign lesions were 287 cases constituting 67.9%, while 
the malignant lesions constituted 24.5% with 104 cases as shown in Table 
10 and Chart 2. 
TABLE 11 DISTRIBUTION OF BENIGN AND 
MALIGNANT LESIONS OF BREAST 
Breast Lesions 
(100 Cases) 
Benign Lesions Malignant 
lesions Non-
Proliferative 
Proliferative 
No. of cases 29 31 40 
Percentage 29% 31% 40% 
 
Out of the total 423 breast cytology cases 100 cases were randomly 
chosen taking into account 40 malignant and 60 benign cases 
encompassing both proliferative (31 cases) and non-proliferative lesions 
(29 cases) as shown in Table 11 and Chart 3. These 100 smears were  
 CHART 1
CHART 2 DISTRIBUTION OF NON
NEOPLASTIC LESIONS ON BREAST CYTOLOGY
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stained with AgNOR stain and examined meticulously for number 
of AgNOR dots and their morphology within the nucleus of the aspirated 
cells. 
TABLE 12 DISTRIBUTION OF BENIGN LESIONS OF THE 
BREAST 
Benign 
breast 
lesions 
(60 Cases) 
Non-Proliferative 
lesions 
(Fibrocystic disease 
/ Fibroadenosis) 
Proliferative lesions 
Epithelial 
Hyperplasia 
Atypical 
Ductal 
Hyperplasia 
Intra 
Ductal 
Papilloma 
No. of cases 29 18 11 2 
Percentage 48.33% 30% 18.33% 3.34% 
 
Out of the 60 cases of benign lesions 29 cases constituting 48.33% 
fall in the group of non-proliferative lesions encompassing fibroadenosis / 
fibrocystic disease. The remaining 31 cases fall into the group of 
proliferative breast lesions with 18 cases of epithelial hyperplasia 
constituting 30%, 11 cases of atypical ductal hyperplasia constituting 
18.33% and 2 cases of intra ductal papilloma constituting 3.34%. These 
findings are shown in Table 12. 
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TABLE 13 QUADRANT DISTRIBUTION OF BREAST 
LESIONS 
Quadrant Number of breast lesions Percentage (%) 
Upper outer 47 47% 
Upper inner 12 12% 
Lower outer 33 33% 
Lower inner 6 6% 
Central  2 2% 
 
The palpable breast lesions were more common in the upper outer 
quadrant comprising 47%, the next to follow is lower outer quadrant 
comprising 33%, followed by upper inner quadrant (12%), lower inner 
quadrant (6%) and finally the central quadrant constituting the least 
number of cases with 2%. These findings were tabulated in Table13 and 
Chart 4. 
TABLE 14 QUADRANT DISTRIBUTION OF BREAST 
CARCINOMAS 
Quadrant Number of breast 
Carcinomas 
Percentage (%) 
Upper outer 19 47.5% 
Upper inner 5 12.5% 
Lower outer 15 37.5% 
Lower inner 1 2.5% 
In our study breast carcinomas were most common in upper outer 
quadrant comprising 47.5% and the least common quadrant to be 
involved is the lower inner quadrant constituting 2.5%. The lower outer  
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quadrant constituting 37.5% and the upper inner quadrant 
constituting 12.5% were the second and the third most commonly 
involved quadrants respectively. These observations are shown in Table 
14 and Chart 5. 
TABLE 15 AGE DISTRIBUTION OF BREAST 
CARCINOMAS 
Age groups Number of breast carcinomas Percentage (%) 
30-39 yrs 3 7.5% 
40-49 yrs 17 42.5% 
50-59 yrs 12 30% 
60-69 yrs 6 15% 
70-79 yrs 2 5% 
 Mean age = 49.5 yrs Average age = 50.5yrs 
 
By dividing the age group of patients into five categories we 
observed that breast carcinomas were more common in the age group of 
40 – 49 years with 17 cases constituting 42.5%, followed by the age 
group of 50 – 59 years with 12 cases comprising 30 % and next to follow 
is the age group of 60 – 69 years with 6 cases constituting 15%. 
The youngest patient in our study is 34 years old and the oldest 
patient in our study is 71 years of age. We arrived at a mean age of 49.5 
years for occurrence of breast carcinoma in our study. These findings are 
tabulated in Table 15 and Chart 6. 
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TABLE 16 CYTOLOGY GRADE DISTRIBUTION OF 
BREAST CARCINOMAS 
Grade  Number of Cases Percentage (%) 
Grade I (6-11 score) 8 20% 
Grade II (12-14 score) 26 65% 
Grade III (15-18 score) 6 15% 
Total 40 100% 
 
All 40 cases of breast carcinomas were graded according to 
Robinson’s grading system into three grades. Grade I carcinoma 
constituted 8 cases with a percentage of 20%, grade II carcinoma 
constituted the majority with 26 cases constituting 65% and grade III 
carcinoma constituted 6 cases with a percentage of 15%. These 
observations are shown in Table16 and Chart 7.  
TABLE 17 CYTOLOGICAL GRADE vs TUMOUR SIZE 
Size of 
tumour 
(cm) 
Grade I 
(%) 
Grade II 
(%) 
Grade III 
(%) 
Total Percentage 
<2 (T1) 2 (25%) 0 0 2 5% 
2– 5 (T2) 6 (75%) 23 (88.5%) 5 (83.3%) 34 85% 
>5 (T3) 0 3 (11.5%) 1 (16.7%) 4 10% 
Total 8 26 6 40 100% 
 
 The association between cytological grade and tumour size was 
made in the Table 17 and Chart 8, which revealed most of the tumours 
(85%) to be in T2 (2 – 5cms) size. Among the Grade I tumours 75% (6  
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cases) were in T2 and 25% (2 cases) were in T1. Among the Grade II 
tumours 88.5% (23 cases) were in T2 and 11.5% (3 cases) were in T3. 
Among the Grade III tumours 83.3% (5 cases) were in T2 and 16.7% 
(1case) was in T3 size. On applying the chi square test for statistical 
significance the P-value was (0.05 ≤ 0.05 – sig). Hence the correlation 
between cytological grade and tumour size was significant. 
TABLE18 CYTOLOGICAL GRADE vs PATIENT AGE 
Patient 
age 
Grade I 
(%) 
Grade II 
(%) 
Grade III 
(%) 
Total Percentage 
30-39 yrs 0 3 (11.5%) 0 3 7.5% 
40-49 yrs 4 (50%) 12 (46.2%) 1 (16.7%) 17 42.5% 
50-59 yrs 2 (25%) 7 (26.9%) 3 (50%) 12 30% 
60-69 yrs 1 (12.5%) 3 (11.5%) 2 (33.3%) 6 15% 
70-79 yrs 1 (12.5%) 1 (3.9%) 0 2 5% 
Total 8 26 6 40  
 
 The Table 18 and Chart 9 depicts that grade III tumours were more 
common in the age group of 50 to 59 years (50%) followed by the age 
group of 60 to 69 years constituting 33.3%. The age group of 40 to 49 
years is the most common age group affected in both grade I (46.2%) and 
grade II (50%) tumours. There was no statistical correlation between 
patient age and tumour grade (P-value – 0.586 > 0.05 – Not sig). 
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TABLE19 CYTOLOGICAL GRADE vs LYMPH NODE STATUS 
Lymph 
node status 
Grade I 
(%) 
Grade II 
(%) 
Grade III 
(%) 
Total Percentage 
Positive  1 (12.5%) 11 (42.3%) 5 (83.3%) 17 42.5% 
Negative  7 (87.5%) 15 (57.7%) 1 (16.7%) 23 57.5% 
Total 8 26 6 40 100% 
  
Among the grade I tumours 87.5% showed negative lymph node 
status and only 12.5% showed positive lymph nodes. On the other hand 
grade III tumours showed 83.3% positive and 16.7% negative lymph 
node status. Grade II tumours showed equivocal findings with 42.3% 
showing lymph node positivity and 57.7% showing lymph node 
negativity. These findings are depicted in Table 19 and Chart 10. There 
was a significant statistical correlation between grade of the tumour and 
lymph node status (P-value – 0.030 < 0.05 – sig). 
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TABLE 20 AgNOR SCORE OF BENIGN vs MALIGNANT 
BREAST LESIONS 
AgNOR 
parameters 
Benign lesions Malignant lesions P-value 
Range Mean S.D. Range Mean S.D. 
Mean  
AgNOR 
1.67-
6.21 
3.55 +/-
1.323 
5.8-
9.54 
7.352 +/-
0.822 
<0.001* 
p AgNOR 
 
3 - 51 23.6 +/-
13.059 
40 - 71 50.875 +/-
6.603 
<0.001* 
AgNOR size 
variation 
0 - 2 0.7 +/-
0.646 
2 – 3 2.25 +/-
0.439 
<0.001* 
AgNOR 
Distribution 
0 - 2 0.717 +/-
0.613 
2 – 3 2.25 +/-
0.439 
<0.001* 
SAPA score 
 
3 - 5 3.717 +/-
0.783 
5 – 8 6.7 +/-
0.883 
<0.001* 
 
 The AgNOR staining and enumeration was done on 100 cases 
which revealed mean AgNOR score of 3.554+/-1.323 in benign lesions, 
while mean AgNOR was higher in malignant lesions with a score of  
7.352+/-0.822. The proliferative AgNOR index also showed higher 
values in malignant lesions (50.875) compared to benign lesions (23.6). 
AgNOR size variation and distribution within nucleus also showed higher 
values in malignant lesions compared to their benign counterparts. Mean 
SAPA score was 6.7 in malignant lesions compared to 3.717 in benign 
breast lesions. All the AgNOR parameters showed a statistically 
significant higher values in malignant lesions compared to the benign 
lesions (P value – 0. 001* < 0.05 – sig).  These findings are tabulated in 
Table 20 and Chart 11 (* - Highly significant value). 
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TABLE 21 AgNOR SCORE OF NON-PROLIFERATIVE vs 
PROLIFERATIVE BREAST LESIONS 
AgNOR 
parameters 
Non-proliferative Proliferative lesions P-value 
Range Mean S.D. Range Mean S.D. 
Mean 
AgNOR 
1.67-
3.35 
2.382 +/-
0.546 
2.78-
6.21 
4.651 +/- 
0.772 
<0.001* 
p AgNOR 
 
3 - 25 12.414 +/-
6.417 
18 – 51 30.065 +/- 
7.929 
<0.001* 
AgNOR size 
variation 
0 - 1 0.172 +/-
0.384 
1 – 2 1.194 +/- 
0.402 
<0.001* 
AgNOR 
Distribution 
0 - 1 0.241 +/-
0.435 
1 – 2 1.161 +/- 
0.374 
<0.001* 
SAPA score 
 
3 - 4 3.034 +/-
0.186 
3 – 5 4.355 +/- 
0.551 
<0.001* 
 
 Out of 60 benign lesions 29 were non-proliferative and 31 were 
proliferative lesions. The proliferative lesions encompassing epithelial 
hyperplasia, intra ductal papilloma and atypical ductal hyperplasia 
showed significantly higher AgNOR values in terms of mean AgNOR, 
proliferative AgNOR index, SAPA score, AgNOR size variation and 
distribution within nucleus, compared to the non-proliferative benign 
lesions encompassing fibrocystic disease / fibroadenosis (Fig. 3-6). These 
AgNOR value showed a statistically significant variation between 
proliferative and non-proliferative lesions of the breast (P-value – 0. 001* 
< 0.05 – sig). These values are shown in Table 21 and Chart 12. 
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TABLE 22 AgNOR SCORE OF PROLIFERATIVE EPITHELIAL 
BREAST LESIONS 
AgNOR 
parameters 
Epithelial 
Hyperplasia 
Atypical 
Ductal 
Hyperplasia 
Intra 
Ductal 
Papilloma 
P-value 
Mean S.D. Mean S.D. Mean S.D. 
Mean 
AgNOR 
4.419 +/-
0.843 
4.903 +/-
0.519 
5.345 +/-
0.686 
<0.001* 
p AgNOR 
 
31.72 +/-
8.498 
36.727 +/-
6.278 
40.5 +/-
2.121 
<0.001* 
AgNOR size 
variation 
1.167 +/-
0.383 
1.182 +/-
0.405 
1.5 +/-
0.707 
0.021<0.05** 
AgNOR 
Distribution 
1.167 +/-
0.383 
1.182 +/-
0.405 
1 0 0.052 
SAPA score 
 
4.333 +/-
0.485 
4.364 +/-
0.674 
4.5 +/-
0.707 
0.542 
  
Out of the 31 benign proliferative epithelial breast lesions, there 
was a gradual and steady increase in AgNOR values from epithelial 
hyperplasia (Fig. 7-10) to atypical ductal hyperplasia (Fig. 11-14) and 
then to intra ductal papilloma (Fig.15-18). But the differences were very 
subtle and there was overlap between the AgNOR counts with regard to 
individual values of these lesions. Only the mAgNOR and pAgNOR 
values were found to be statistically significant in differentiating various 
subtypes of benign proliferative epithelial breast lesions (P-value – 0. 
001* < 0.05 – sig). These values are tabulated in Table 22. 
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TABLE 23 ROBINSON’S SCORE vs mAgNOR SCORE 
No of 
cases 
Robinson 
Grade 
Robinson’s Score Mean AgNOR P-value 
Range Mean S.D. Range Mean S.D. 
8 I 7-10 8.875 +/-
1.125 
5.8-
7.36 
6.569 +/-
0.648 
<0.001* 
26 II 12-14 12.96 +/-
0.774 
6–8.71 7.37 +/-
0.656 
<0.001* 
6 III 15-17 16.17 +/-
0.753 
7.87-
9.84 
8.322 +/-
0.647 
<0.001* 
 
 Correlation between the Robinson’s score and AgNOR score in the 
40 cases of malignant breast neoplasm is tabulated in Table 23. The mean 
AgNOR score showed a gradual increase in correlation with the 
Robinson’s score and thus with the grade of the carcinomatous lesion. 
The mean AgNOR score and the Robinson’s score showed a statistically 
significant correlation with regard to malignant neoplasm of breast (P-
value – 0. 001* < 0.05 – sig). 
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TABLE 24 ROBINSON’S SCORE vs pAgNOR SCORE 
No of 
cases 
Robinson 
Grade 
Robinson’s Score pAgNOR P-value 
Range Mean S.D. Range Mean S.D. 
8 I 7 - 10 8.875 +/-
1.125 
40 - 52 44.5 +/-
4.472 
<0.001* 
26 II 12-14 12.96 +/-
0.774 
41 - 62 51.12 +/-
4.893 
0.141 
6 III 15-17 16.167 +/-
0.753 
49 - 71 58.34 +/-
7.763 
<0.001* 
 
 As with the mean AgNOR score the proliferative AgNOR index 
also showed a good correlation with that of Robinson’s score. The 
proliferative AgNOR index score increased with increasing grades of the 
Robinson’s grading system for breast carcinomas. But these were 
significant statistically only for grade I (Fig. 19-22) and grade III tumours 
(Fig. 27-30) (P-value – 0. 001* < 0.05 – sig) and not for grade II tumours 
(Fig. 23-26) (P-value – 0.141 > 0.05 – Not sig). The findings are depicted 
in Table 24. 
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TABLE 25 ROBINSON’S SCORE vs AgNOR SIZE VARIATION 
No of 
cases 
Robinson 
Grade 
Robinson’s Score AgNOR size variation P-value 
Range Mean S.D. Range Mean S.D. 
8 I 7-10 8.875 +/-
1.125 
2 - 2 2 +/- 0 <0.001* 
26 II 12-14 12.96 +/-
0.774 
2-3 2.154 +/-
0.368 
<0.001* 
6 III 15-17 16.167 +/-
0.753 
3 - 3 3 +/- 0 <0.001* 
 
  
There was an increased variation in the size of the AgNOR dots as 
the Robinson’s cytology grade of the malignant breast neoplasm 
increased. Thus AgNOR dot size variation correlated very well with that 
of Robinson’s scoring system and is of statistical significance (P-value – 
0. 001* < 0.05 – sig). These findings were depicted in Table 25. 
TABLE 26 ROBINSON’S SCORE vs AgNOR DISTRIBUTION IN 
NUCLEI 
No of 
cases 
Robinson 
Grade 
Robinson’s Score AgNOR distribution in 
nuclei P-value 
Range Mean S.D. Range Mean S.D. 
8 I 7 - 10 8.875 +/-
1.125 
2 - 2 2 +/- 0 <0.001* 
26 II 12 -14 12.96 +/-
0.774 
2-3 2.154 +/-
0.368 
<0.001* 
6 III 15-17 16.167 +/-
0.753 
3 - 3 3 +/- 0 <0.001* 
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 There was an increased dispersion of AgNOR dots within the 
nucleus as the cytology grade of the malignant neoplasm increased. Thus 
there is a statistically significant correlation between AgNOR dot 
distribution and Robinson’s cytology score (P value – 0. 001* < 0.05–sig) 
as shown in Table 26. 
TABLE 27 ROBINSON’S SCORE vs SAPA SCORE 
No of 
cases 
Robinson 
Grade 
Robinson’s Score SAPA score P-value 
Range Mean S.D. Range Mean S.D. 
8 I 7 - 10 8.875 +/-
1.125 
5 - 7 5.75 +/-
0.707 
<0.001* 
26 II 12-14 12.96 +/-
0.774 
6 - 8 6.731 +/-
0.368 
<0.001* 
6 III 15-17 16.167 +/-
0.753 
7 - 8 7.833 +/- 
0.378 
<0.001* 
 
The SAPA score of the malignant breast neoplasm increased as the 
grade and thus the aggressiveness of the neoplasm increased. Thus SAPA 
score and Robinson’s cytology score goes hand in hand with each other. 
The SAPA score and the Robinson’s cytology score showed a statistically 
significant correlation with regard to malignant neoplasm of breast (P-
value – 0. 001* < 0.05 – sig). These findings are shown in Table 27. 
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TABLE 28 AgNOR SCORE vs LYMPH NODE STATUS 
AgNOR parameters Negative lymph nodes Positive lymph nodes 
Mean S.D. Mean S.D. 
Mean AgNOR 7.045 +/-0.763 7.768 +/-0.726 
p AgNOR 49.565 +/-6.57 52.647 +/-6.412 
AgNOR size 
variation 
2.13 +/-0.344 2.412 +/-0.507 
AgNOR 
Distribution 
2.13 +/-0.344 2.412 +/-0.507 
SAPA score 6.391 +/-0.783 7.117 +/-0.857 
  
The patients with positive lymph node status show a mild increase 
in AgNOR values compared to that of node negative patients. The 
AgNOR score is not of much significance in delineating these patients 
according to lymph node status. All the parameters of AgNOR values 
with regard to lymph node status are shown in Table 28. 
TABLE 29 ROBINSON’S SCORE vs LYMPH NODE STATUS 
Lymph node status Robinson’s Score 
Mean S.D. 
Negative lymph nodes 11.826 +/-2.289 
Positive lymph nodes 13.706 +/-2.054 
 
 The Robinson’s score also showed not much of a significant 
variation in the values with regard to the axillary lymph node status of the 
patients, these findings were tabulated in Table 29. 
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TABLE 30 AgNOR SCORE vs TUMOUR SIZE 
AgNOR 
parameters 
< 2 cms (T1) 2 – 5 cms (T2) > 5 cms (T3) P-value 
Mean S.D. Mean S.D. Mean S.D. 
Mean 
AgNOR 
6 +/-
0.198 
7.332 +/-
0.644 
8.2 +/-1.427 <0.001* 
p AgNOR 
 
41.5 +/-
2.121 
50.912 +/-
5.160 
55.25 +/-13.72 <0.001* 
AgNOR size 
variation 
2 0 2.206 +/-
0.410 
2.75 +/-0.5 <0.001* 
AgNOR 
Distribution 
2 0 2.206 +/-
0.410 
2.75 +/-0.5 <0.001* 
SAPA score 6 0 6.765 +/-
0.699 
7.5 +/-1.00 <0.001* 
  
There was a good correlation between the AgNOR values and the 
tumour size. The AgNOR counts increased gradually as the size of the 
malignant neoplasm increased, with T1 lesions showing a mAgNOR 
count of 6, T2 lesions showing a mAgNOR count of 7.332 and T3 lesions 
showing the highest mean AgNOR count of 8.2. The AgNOR score and 
the size of the breast neoplasm showed a statistically significant 
correlation between them (P-value – 0. 001* < 0.05 – sig). These 
observations were depicted in Table 30. 
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TABLE 31 ROBINSON’S SCORE vs TUMOUR SIZE 
Tumour Size Robinson’s Score P-value 
Mean S.D. 
< 2 cms (T1) 7.5 +/-0.707  
<0.001* 2 – 5 cms (T2) 12.735 +/-2.064 
> 5 cms (T3) 14.25 +/-2.062 
 
The Robinson’s score also showed a gradual increase in the values 
as the size of tumour increased with T1 lesions having a mean value of 
7.5, T2 lesion showing a mean value of 12.735 and finally T3 lesion had 
the highest mean value of 14.25. Hence there is a statistically significant 
correlation between Robinson’s score and the size of the breast neoplasm 
(P-value – 0. 001* < 0.05 – sig). These observations were shown in         
Table 31. 
 Out of the 40 breast malignancies detected by cytology all were 
confirmed by histopathological examination. 5 cases were found to be of 
grade I tumours, 20 were of grade II tumours and 15 were of grade III 
tumours according to Bloom and Richardson histological grading system 
  Among the 8 breast carcinoma cases detected by cytology as 
Robinson’s grade I lesions 5 turned out to be of grade I in histology while 
remaining 3 turned out to be grade II tumours in histology. Out of the 26 
cases detected to be grade II lesions in cytology 17 turned out to be of the 
same grade in histology while the remaining 9 cases belonged to grade III 
tumours in histology. Of the 6 cases detected to be grade III lesions in 
cytology all turned out to be of the same grade III in histology. 
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DISCUSSION 
 The initial step in the evaluation of any patient presenting with a 
palpable breast lesion is to distinguish benign lesions from malignant 
ones. Fine Needle Aspiration Cytology (FNAC) being a simple, rapid, 
less invasive and cost effective preoperative out-patient procedure plays 
an immense role in the management of these types of lesions. It can also 
provide additional information relevant for diagnosis and treatment38. But 
FNAC does pose an increasing challenge and diagnostic dilemmas in 
certain situations. This can to a certain extent be overcome by using an 
ancillary cell proliferative marker in the form of AgNOR stain which is a 
simple, one step silver staining technique. 
 AgNORs can be easily demonstrated in routinely fixed cytology 
smears and can even be applied on already H & E stained smears after de-
staining them. The frequency, number and dispersion of AgNOR dots are 
consistently higher in malignant neoplasm compared to the benign 
neoplasm of breast. In this regard AgNORs have been attracting much 
attention as a proliferative marker and as an indicator for aggressiveness 
of the lesion and has a potential value in diagnostic cytology52. 
Robinson’s cytological method of grading was found to be more 
specific compared to other cytological grading methods when Bloom and 
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Richardson histological grading system is taken as a gold standard in the 
study conducted by Das et al35. 
Our present study was conducted on 100 cases of breast lesions 
encompassing both benign (proliferative and non-proliferative) and 
malignant lesions. The cytology smears were stained with both 
Hematoxylin & Eosin and AgNOR stains. The AgNOR dot number and 
morphology is enumerated meticulously in each case and the findings 
tabulated. Similarly Robinson’s score was also calculated for each 
individual case and findings tabulated. The current study evaluates the 
significance of AgNOR score in distinguishing benign from malignant 
neoplasm of breast, and also in differentiating non-proliferative from 
proliferative breast lesions. The study also evaluates the significance of 
AgNOR score in relation to Robinson’s score in the grading of malignant 
breast lesions. 
 Our study includes 100 cases of breast lesions of which 40 cases 
were malignant and 60 cases were benign lesions. Among the benign 
lesions 29 cases were non-proliferative breast diseases encompassing 
fibroadenosis / fibrocystic disease, the remaining 31 cases were 
proliferative breast lesions including 11 cases of atypical ductal 
hyperplasia, 18 cases of epithelial hyperplasia and 2 cases of intra ductal 
papilloma. 
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In the studies conducted by Mi-Jung Kim et al in 2006 showed a 
mean age of 47.4 years for breast carcinomas, Gloria Piero et al. in the 
same year showed a mean age of 54 years and Aye Aye Thike et al. in 
2010 showed a mean age of 53 years for patients presenting with breast 
carcinomas. In our present study age of the patients ranged from 17 years 
to 71 years. Among the malignant lesions the youngest patient was of 34 
years and the oldest patient was of age 71 years. Among the benign 
lesions the youngest patient was of age 17 years and the oldest patient 
was of age 69 years. Among 40 cases of malignant lesions the mean age 
of the patient was 49.5 years, and the mean age group was 40 – 49 years, 
which correlated with the above studies conducted by Mi-Jung Kim et al, 
Gloria Piero et al and Aye Aye Thike et al. 
 Studies conducted by Azzopardi20 and Weidner68 showed upper 
outer quadrant to be the most common quadrant involved by breast 
carcinoma, the least common quadrant to be involved was the lower inner 
quadrant. Our present study correlated with the findings of the above 
studies showing 47 % of the breast lesions to be localised to upper outer 
quadrant followed by lower outer quadrant having 33% of cases, the least 
common quadrant affected in our study was central quadrant accounting 
2%. Among the malignant breast lesions the most common quadrant 
affected was upper outer accounting for 47.5% followed by lower outer 
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accounting for 37.5%, the least common quadrant was lower inner 
constituting 2.5%.  
 Study conducted by Lobna Ayadhi et al69 showed T2 size lesions 
forming the majority (63.2%) of the breast carcinomas, followed by T3 
and T1 sized lesions. Kakil Rassul et al70 also showed similar findings 
with T2 lesions being most common followed by T3 and T1 lesions. 
While Lakmini et al71 showed T3 lesions being more common followed 
by T2 and T1. Our present study showed a higher percentage of tumours 
to be in the T2 size group (85%), followed by T3 lesions showing 10% 
and T1 lesions showing 5%. Our findings were similar to the studies 
conducted by Lobna Ayadhi et al and Kakil Rassul et al, while 
contradicts the study conducted by Lakmini et al. 
 Studies carried out by Carey et al72 and Madhuri et al73 showed 
grade III tumours of the breast to be the most common constituting 49% 
followed by grade II tumours. While our present study showed the grade 
II tumours of the breast to be more frequent than other grades constituting 
65% followed by grade I and grade III tumours which constituted 20% 
and 15% respectively. Our findings differed from the above mentioned 
studies.  
 
 
75 
 
AgNOR – BENIGN LESIONS: 
 Simba M et al62 had a mean AgNOR count of 1.8 for benign 
lesions of the breast. Dasgupta A et al74 also reported similar mean 
AgNOR value of 1.61 for benign breast lesions and Kumar A et al63 
demonstrated the mean AgNOR count of 1.88 in the benign breast 
lesions. Whereas Reddy GS et al.59 reported a higher mAgNOR count of 
7.45 and Drevan PA et al.65 had a wide range of values for mAgNOR of 
benign lesions of breast ranging from 2.65 to 6.8 similar to that of our 
study. In our present study the mean AgNOR values were consistently 
higher in malignant neoplasm compared to the benign neoplasm and were 
also statistically significant. The mean AgNOR count of benign neoplasm 
(60 cases) was 3.55+/-1.323, with wide range of values ranging from 1.67 
to 6.21 and a SAPA score of 3.72. 
 Among the 60 cases of benign lesions 29 cases of non-proliferative 
breast lesions showed a mean AgNOR count of 2.38 with values ranging 
from 1.67 to 3.35 and a SAPA score of 3.03, the remaining 31cases of 
proliferative breast lesions showed a higher mean AgNOR score of 4.651 
with values ranging from 2.78 to 6.21 and a SAPA score of 4.35. The 
mean AgNOR, proliferative AgNOR index, AgNOR size variation, 
pattern of AgNOR distribution within nucleus and SAPA score all 
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showed a higher AgNOR values in proliferative lesions compared to non-
proliferative lesions of breast. 
 Among the 31 cases of proliferative breast lesions 18 cases of 
epithelial hyperplasia showed a mean AgNOR value of 4.419+/-0.843 
and a SAPA score of 4.333+/-0.485, 11 cases of atypical ductal 
hyperplasia showed mAgNOR value of 4.903+/-0.519 and a SAPA score 
of 4.364+/-0.674 and 2 cases of intraductal papilloma showed mAgNOR 
value of 5.345+/-0.686 and a SAPA score of 4.5+/-0.707. The variation in 
AgNOR values between the different subtypes of proliferative breast 
lesions is very subtle. The mAgNOR and pAgNOR values were only 
found to be statistically significant in differentiating subtypes of benign 
proliferative epithelial breast lesions on cytology (P-value – 0. 001* < 
0.05 – sig). While AgNOR size variation, pattern of AgNOR distribution 
within nucleus and SAPA score are not found to be of much significance. 
There are a few overlaps between AgNOR score with regard to individual 
values of different subtypes. 
AgNOR – MALIGNANT LESIONS: 
 Kim A75 reported a mean AgNOR count for malignant breast 
lesions as 5.09, Simba M et al62 had a lower mean AgNOR count of 3.5 
for malignant breast lesions compared to our study, while Kumar A et al63 
reported a mAgNOR count of 6.57 for malignant lesions which was 
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similar to our study. Whereas Dasgupta A et al74 reported a higher 
mAgNOR value of 12.10 for malignant breast lesions, similar to that of 
Reddy GS et al59 who reported a value of 12.72 for breast malignancies. 
Drevan PA et al65 reported a wide range of values for mAgNOR from 4.6 
to 26.9 with respect to malignant breast lesions. 
In our present study malignant breast neoplasm showed a 
mAgNOR value of 7.352+/-0.822 with individual values ranging from 
5.8 to 9.54 and with a SAPA score of 6.7. Among 40 malignant lesions 8 
cases of grade I tumours showed a mAgNOR value of 6.569+/-0.648 with 
a SAPA score of 5.75, grade II tumours showed a mAgNOR value of 
7.37+/-0.656 with a SAPA score of 6.73 and grade III tumours showed a 
mAgNOR value of 8.322+/-0.647 with a SAPA score of 7.83. There was 
a steady increase in mAgNOR values and SAPA score in concordance 
with the grade of the lesions. The mAgNOR values showed a statistically 
significant correlation with the Robinson’s cytological grade. All the 
other AgNOR parameters also showed a gradual and steady increase in 
the values as the Robinson’s cytological grade of the tumour progressed 
higher and was found to be statistically significant. 
MALIGNANT VS BENIGN LESIONS: 
 Simba M et al62, who studied the cytology of 200 breast cases 
including 140 malignancies, 55 benign lesions and 5 normal breasts came 
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out with the finding that AgNOR values are much higher in malignant 
neoplasm compared to the benign ones. The study conducted by 
Dasgupta A et al74 showed AgNOR values are of not much significance 
in differentiating between two subtypes of benign lesion (fibroadenoma 
and fibrocystic disease) which was in concordance with our study. He 
also showed higher AgNOR values for malignancies compared to benign 
lesions. 
 Roller E et al.58 had similar findings with higher AgNOR counts 
for malignant neoplasm of breast compared to benign neoplasm. Reddy 
GS, Sesikeran B, Bhaskaran CS59 conducted study on 10 benign and 
malignant epithelial lesions of breast and found higher AgNOR values for 
malignant lesions compared to benign lesions. Hasnan J, Jayaram G40 
conducted a study on 31 cases of benign lesions and 25 cases of 
malignant lesions of breast and made observations that AgNOR value in 
benign lesions ranged from 2.55 to 5.0 in contrast with malignant lesions 
which showed values ranging from 5.8 to 17.2, they also observed that 
there was no overlap between the AgNOR values of benign and 
malignant lesions of breast. 
Meehan SM, Carney DN, Magee H, Dervan PA54 conducted a 
study on the value of AgNOR in differentiating malignant and benign 
breast lesions in cytology. They observed a mean AgNOR value of 4.44 
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for benign breast lesions and 9.52 for malignant breast lesions. They 
arrived at a median AgNOR score of 7 for benign lesions and 13 for 
malignant lesions. They put forth a diagnostic accuracy of 90% for 
AgNORs in differentiating benign from malignant lesions. 
Khanna AK, Kumar M, Ansari MA, Khanna A64 assessed 27 
benign and 46 malignant breast lesions. They used two parameters both 
Subjective AgNOR Pattern Assessment (SAPA) score and mean AgNOR 
count. They found that mAgNOR score and SAPA were quite similar in 
differentiating benign from malignant lesions. The mean AgNOR score of 
benign lesion was 2.75 compared to malignant lesion which showed a 
value of 6.94. These findings are similar to that observed in our study. 
This study showed a SAPA score of 5.87 for benign lesions compared to 
9.02 for malignant lesions. Similarly Kumar A, Kumar M, Kushwaha 
AK, Gupta S63 also had higher AgNOR values for malignant lesions 
compared to benign lesions of breast. 
Karmakar T, Radhika S, Gupta SK60 found a higher mean AgNOR 
value of 16.63 for malignant lesion and mean AgNOR value of 6.39 for 
benign lesions. The overall AgNOR values are higher compared to our 
study. They concluded by putting forth a cut-off value of 11 for 
differentiating benign from malignant lesions. Mehrotra A, Chandra T61 
assessed the cytological smears of 64 malignant and 31 benign neoplasm 
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of breast and concluded by stating that the cut off point of 4 can be used 
in differentiating benign from malignant breast lesions with regard to 
mean AgNOR counts. 
Our present study showed a statistically significant difference 
between the AgNOR values of benign lesions compared to that of 
malignant lesions of breast. Our study showed a mAgNOR value of 
3.554+/-1.323 for benign lesions with individual values ranging from 
1.67 to 6.21. While the malignant lesions showed a mAgNOR value of 
7.352+/-0.822 with individual values ranging from 5.8 to 9.54. Our study 
showed mean pAgNOR value of 23.6+/-13.059 for benign lesions 
compared to the mean pAgNOR value of 50.875+/-6.603 for malignant 
lesions of breast. Our present study showed a considerable variation in 
the AgNOR size and distribution within nucleus for malignant neoplasm 
compared to a meagre variation in the AgNOR size and distribution for 
the benign neoplasm of breast. Our study also showed a higher mean 
SAPA score of 6.7+/-0.883 for malignant neoplasm compared to lower 
mean SAPA score of 3.717+/-0.783 for benign neoplasm of breast. 
In a study by Dhakhwa R et al55 on 110 breast lumps they observed 
that if the cut off score for AgNOR count / nucleus is taken as 6 
specificity is 88.9%, sensitivity is 89.5% and if the cut off value for 
SAPA score is taken as 8 specificity is 83.3%, sensitivity is 89.5% for 
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differentiating benign from malignant neoplasms. From our study we 
observed that a mAgNOR cut off value of 6 and SAPA score cut off 
value of 5 can be effectively utilised in differentiating benign from 
malignant neoplasm of the breast with a sensitivity of 92.5% and 
specificity of 90%. 
Ruschoff J, Plate K, Contractor H, Neumann K, Thomas C76 found 
a considerable overlap of mean AgNOR score between malignant and 
benign lesions. They found the mAgNOR values for benign lesions in the 
range of 1.2 to 3.8 and the mAgNOR values for malignant lesions in the 
range of 1.5 to 16.2. Giri DD, Dundas SA, Lawry J, Nottingham JF, 
Underwood JC77 also noted overlapping of AgNOR counts in 25 to 30% 
of carcinomas with epithelial hyperplastic lesions in the range of 2 to 3 
AgNOR dots per nuclear profile. In our present study 3 of the cases, 2 
from epithelial hyperplasia and 1 from atypical ductal hyperplasia 
showed a mild overlap in the mAgNOR count with that of malignant 
lesions of breast. 
There was a considerable variation in the absolute value of mean 
AgNOR counts by different studies. These can be attributed to the fact 
that different authors count AgNOR dots differently, some authors count 
clustered dots as a single dot when individual NORs could not be easily 
discerned, while others leave off such cells where NORs could not be 
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easily discerned. This explains for the variation in the values of mean 
AgNOR count. Crocker et al53 recommended the counting of 100 cells as 
a standardised approach to AgNOR dot enumeration and this was 
followed in our study. 
AgNOR AS PROGNOSTIC INDICATOR: 
 The histological grade, tumour size and the lymph node status 
forms the most important prognostic indicators for carcinoma of breast. 
  Kesari AL et al67, Subramanian S, Shariff S and Karmakar T, 
Radhika S, Gupta SK60 and  Andrade C78 proved in their study that 
tumours showing higher AgNOR counts were of higher grade and are 
poorly differentiated. Gimenez Mas JA et al79 and Ofner D et al80, noted 
that there was a significant association between tumour grade and the 
mean AgNOR values, and the AgNOR values increased as the grading 
increased. However various other authors like Kumar A et al63, Raymond 
WA, Leong AS51 and Gupta GR et al81, came to a conclusion that no 
correlation significance was found between tumour grade and mAgNOR 
values. Kazuhiko Hatano82 also showed no correlation between mAgNOR 
count and the grade of the tumour. In his study grade I tumours showed a 
mAgNOR count of 4.71 +/- 1.17, and grade II tumours showed a 
mAgNOR count of 4.38 +/- 1.41 and grade III tumours showed a 
mAgNOR count of 5.42 +/- 1.63. 
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 In our present study 40 breast carcinomas detected by cytology 
were confirmed by histology and were graded using Bloom and 
Richardson histological grading system. According to this grading system 
5 cases (12.5%) constituted grade I tumours of which all 5 cases were 
previously graded as Robinson’s cytological grade I, 20 cases (50%) 
constituted grade II tumours among which 17 cases were graded in 
cytology as Robinson’s cytological grade II and the remaining 3 were 
graded as Robinson’s cytological grade I. the remaining 15 cases (37.5%) 
constituted grade III tumours among which 9 cases had been graded as 
Robinson’s cytological grade II while the remaining 6 were graded as 
Robinson’s cytological grade III. 
  Kumar A et al. 63 and Gupta GR et al. 81, Gimenez-Mas JA et 
al.79 showed that there was a significant association between tumour size 
and AgNOR values and the mAgNOR count increased as the tumour size 
increased. Rajeevan K, Aravindan KP and Kumari BC83 proved that the 
mean AgNOR count was much higher in tumours greater than 5 cms. 
Whereas other authors like Hehir DJ et al84, and Raymond WA, Leong 
AS51 noted that the tumour size did not correlate well with the mean 
AgNOR counts. 
 In our present study of 40 breast cancers, 2 cases was of T1 size 
lesions, 34 cases were of T2 size lesions and remaining 4 cases 
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constituted T3 size lesions. The mean AgNOR count of T1 size lesion 
was 6+/-0.198, the mean AgNOR count of T2 size lesion was 7.332+/-
0.644 and the mean AgNOR count of T3 size lesion was 8.2+/-1.427. 
These observations showed a gradual increase in mean AgNOR values as 
the tumour size increased, similar to the findings of the above mentioned 
studies. 
 Status of the axillary lymph nodes is one of the most important 
prognostic indicators of the carcinoma of breast. In our study of 40 cases, 
17 cases (42.5%) showed positive lymph node status, while the remaining 
23 cases (57.5%) showed negative lymph nodes. The cases with positive 
lymph nodes expressed a mean AgNOR count of 7.768+/-0.726, while 
the cases with negative lymph nodes expressed mean AgNOR count of 
7.045+/-0.763. These differences in AgNOR values are subtle and are not 
of much significance as there is only a minor variation. In our study 
AgNOR values does not correlate much with that of lymph node status as 
there was overlap with regard to individual values.  
 Studies conducted by various authors like Karmakar T, Radhika S, 
Gupta SK60 , Aubele M, Jutting U, Auer G,85 Hehir DJ et al,84 and 
Raymond WA, Leong AS51 also confirmed our finding by observing no 
correlation between lymph node status and AgNOR values. 
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Study conducted by Simha M, Menon M, Doctor V62 also proves 
that no correlation was found between AgNOR values and lymph node 
status. While studies conducted by Kumar A et al63, Gupta GR et al81 
Gimenez-Mas JA et al79 showed a significant correlation between lymph 
node status and the mean AgNOR values.  
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SUMMARY 
 Fine Needle Aspiration Cytology as a preoperative diagnosis is 
primarily aimed at distinguishing benign from malignant neoplasm. But 
pathologists are sometimes fraught with diagnostic dilemmas in cytology. 
In such difficult situations, AgNOR as a proliferative marker is of great 
help in differentiating benign from malignant neoplasm of the breast. 
AgNOR staining as a simple one step silver staining technique can 
be reliably and effectively utilised to differentiate malignant from benign 
neoplasm of the breast. The malignant neoplasm consistently showed 
higher AgNOR values compared to their benign counterparts. 
Various studies has shown a wide discrepancy between the 
absolute value of mean AgNOR counts and the cut off values for 
differentiating benign from malignant neoplasm of breast. This variation 
could have stemmed up from the fact that there was a lack of 
standardisation in the counting of AgNOR dots and also due to inter 
observer variability. 
Our study has tried to prove that AgNORs can reliably be used to 
differentiate benign non-proliferative lesions from the proliferative 
lesions of breast, the latter showing consistently higher values compared 
to the non-proliferative lesions. This is due to the fact that AgNORs act a 
marker of cellular proliferative activity. 
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In our study while meticulously examining the AgNOR dots we 
took into consideration five AgNOR parameters for evaluating the NORs. 
They are mean AgNOR count, proliferative AgNOR index, AgNOR size 
variation, AgNOR distribution within the nucleus and the Subjective 
AgNOR Pattern Assessment (SAPA) score. All these parameters showed 
consistency in their scoring pattern and showed higher values for 
malignant tumours compared to the benign ones. 
Our study showed very good correlation of all the AgNOR 
parameters with the Robinson’s cytological grading system with regard to 
malignant neoplasm of breast. All the AgNOR parameters showed a 
consistent and steady increase in their values as the cytological grade of 
tumour progressed higher. 
Regarding AgNORs being considered as a cell proliferation 
marker, it showed a consistent and steady increase in the AgNOR values 
from benign non-proliferative neoplasm to benign proliferative neoplasm 
and then onto malignant neoplasm of the breast which showed the highest 
AgNOR value. As a proliferative marker AgNOR is used to predict the 
biological behaviour of breast neoplasm. In our study the AgNOR 
parameters did not show a significant correlation with the lymph node 
status of our patients, but showed a significant correlation with the 
tumour size and grade of the breast neoplasm. Hence it can be stated that 
AgNORs can be utilised as a prognostic indicator in the breast neoplasm. 
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CONCLUSION 
Assessment and evaluation of the AgNORs and their parameters in 
the present study on breast cytology smears has enlightened us to draw 
the following conclusions- 
 All the AgNOR parameters showed consistently higher values for 
malignant neoplasm compared to the benign neoplasm of the 
breast. Mean AgNOR score and SAPA score was found to be more 
superior compared to other AgNOR parameters and provide 
additional information in cases that provide diagnostic difficulty in 
routine FNAC. SAPA score was more reproducible compared to 
mAgNOR count. 
 AgNORs are helpful in differentiating benign proliferative 
neoplasm from non-proliferative neoplasm of breast. The 
proliferative neoplasm showed higher AgNOR values compared to 
the non-proliferative neoplasm of the breast. 
 AgNOR showed a good correlation with the Robinson’s 
cytological grading system and the AgNOR values increased as the 
cytological grade of the neoplasm progressed higher. 
 As cell proliferative marker mAgNOR count and SAPA score 
represent proliferating cellular activity and hence predict the 
biological behaviour of the breast neoplasm. 
FIBROCYSTIC DISEASE 
 
 
Figure 3 Aspirate of fibrocystic change showing 
honeycombing of uniform ductal epithelial cells 
with bipolar naked nuclei in the background 
(H&E, 100X) 
 
 
Figure 5 Duct epithelial cell clusters in 
honeycomb arrangement showing only a few 
AgNOR dots (AgNOR, 400X) 
 
 
 
Figure 4 Uniform duct epithelial cell clusters in 
fibrocystic change of breast (H&E, 400X) 
 
 
 
Figure 6 Uniform duct epithelial cell clusters 
showing only a few AgNOR dots (AgNOR, 
400X) 
 
EPITHELIAL HYPERPLASIA 
 
 
 
Figure 7 Large slightly disorganised sheets of 
hyperplastic duct epithelial cell clusters with 
tendency to streaming (H&E, 100X) 
 
 
Figure 9 Large sheets of hyperplastic duct 
epithelial cell clusters showing 3-4 AgNOR dots 
per nucleus (AgNOR, 400X) 
 
 
 
 
Figure 8 Large sheet of hyperplastic duct 
epithelial cell clusters (H&E, 400X) 
 
 
 
Figure 10 Hyperplastic duct epithelial cells in 
cohesive clusters showing 3-4 AgNOR dots per 
nucleus (AgNOR, 400X) 
 
ATYPICAL DUCTAL HYPERPLASIA 
 
 
 
Figure 11 Large sheets of mildly atypical duct 
epithelial cells with holes indicating a cribriform 
pattern (H&E, 100X) 
 
 
Figure 13 Atypical hyperplastic duct epithelial 
cell cluster of breast showing 4-5 AgNOR dots per 
nucleus (AgNOR, 400X) 
 
 
 
Figure 12 Large slightly disorganised sheet of 
mildly atypical duct epithelial cells (H&E, 400X) 
 
 
 
Figure 14 Cluster of hyperplastic duct epithelial 
cells with atypia showing 4-5 AgNOR dots per 
nucleus (AgNOR, 400X) 
INTRADUCTAL PAPILLOMA 
 
 
 
Figure 15 Finger like papillary structures seen in 
intraductal papilloma of breast (H&E, 400X) 
 
 
 
Figure 17 Finger like papillary structures of 
breast showing 4-5 AgNORs per nucleus 
(AgNOR, 400X) 
 
 
 
Figure 16 Papillary fragments of the duct 
epithelial cells of breast (H&E, 400X) 
 
 
 
 
Figure 18 Papillary structures with fibrovascular 
core showing 4-5 AgNORs per nucleus (AgNOR, 
400X) 
BREAST CARCINOMA – GRADE 1 
 
 
 
Figure 19 Cell rich dyscohesive clusters of 
epithelial cells with mild atypia of nucleus (H&E. 
400X) 
 
 
Figure 21 Dyscohesive clusters of pleomorphic 
duct epithelial cells showing increased number of 
AgNORs per nucleus (AgNOR, 400X) 
 
 
 
Figure 20 Dyscohesive clusters of epithelial cells 
with mild cellular pleomorphism with nuclear 
overlapping (H&E, 400X) 
 
 
Figure 22 Clusters of duct epithelial cells with 
mild nuclear pleomorphism showing increased 
number of AgNORs per nucleus (AgNOR, 400X) 
BREAST CARCINOMA – GRADE 2 
 
 
 
Figure 23 Dyscohesive clusters of epithelial cells 
with moderate nuclear pleomorphism (H&E, 
400X) 
 
 
Figure 25 Clusters of duct epithelial cells with 
moderate nuclear pleomorphism showing higher 
number of AgNORs per nucleus (AgNOR, 400X) 
 
 
 
Figure 24 Dyscohesive clusters of epithelial cells 
with moderate nuclear enlargement and atypia 
(H&E, 400X) 
 
 
Figure 26 Dyscohesive clusters of epithelial cells 
with moderate nuclear atypia showing higher 
number of AgNORs per nucleus (AgNOR, 400X) 
BREAST CARCINOMA – GRADE 3 
 
 
 
Figure 27 Poorly cohesive clusters of duct 
epithelial cells showing nuclear enlargement and 
pleomorphism (H&E, 400X) 
 
 
Figure 29 Poorly cohesive clusters of duct 
epithelial cells showing showing numerous 
AgNORs per nucleus (AgNOR, 400X) 
 
 
 
Figure 28 Highly dyscohesive clusters of duct 
epithelial cells showing obvious nuclear 
enlargement & overlapping (H&E, 400X) 
 
 
Figure 30 Highly dyscohesive clusters of duct 
epithelial cells showing numerous AgNORs per 
nucleus (AgNOR, 400X) 
mAgNOR pAgNOR AgNOR SIZE AgNOR DIS SAPA
1 82531 870/11 38 F R LOQ 4 DC NEG 7.41 58 2 2 7 13 II DC-II
2 82577 872/11 58 F R UIQ 4 DC POS 7.56 51 2 2 7 13 II DC-III
3 23654 1008/11 33 F R LOQ 1 EPI 4.68 34 1 1 4
4 96254 1110/11 50 F L UOQ 0.5 FCD 2.87 18 1 1 3
5 123917 1383/11 50 F R UIQ 5 DC POS 8.54 62 3 3 8 17 III DC-III
6 36244 1541/11 65 F R LOQ 5 DC POS 7.94 49 3 3 8 16 III DC-III
7 139309 1544/11 37 F L LOQ 2.5 ADH 4.92 34 1 1 4
8 37421 1574/11 50 F L LOQ 4.5 DC POS 8.71 49 3 3 8 14 II DC-III
9 171607 1881/11 42 F L UOQ 4 DC POS 7.57 48 2 2 7 12 II DC-II
10 188019 2060/11 69 F L LOQ 1 FCD 1.86 11 0 0 3
11 50573 2088/11 56 F R UOQ 5.5 DC POS 8.52 47 3 3 8 14 II DC-III
12 196648 2093/11 49 F L LOQ 4 DC NEG 7.63 50 2 2 7 12 II DC-III
13 50958 2100/11 49 F R UIQ 3.5 DC POS 6.87 45 2 2 6 12 II DC-II
14 53933 2205/11 59 F R UIQ 4.5 DC POS 7.07 49 2 2 6 12 II DC-II
15 212201 2211/11 40 F R UOQ 1.5 EPI 3.79 28 1 1 4
16 211989 2216/11 65 F R UOQ 2 ADH 3.87 24 1 1 3
17 2186 028/12 50 F L LOQ 1 EPI 3.83 21 1 1 4
18 2913 087/12 26 F L UOQ 0.5 FAD 1.71 6 0 0 3
19 12458 114/12 42 F R UOQ 2 ADH 4.86 38 1 1 4
20 11490 127/12 42 F L UOQ 4 DC NEG 7.97 55 2 2 7 14 II DC-III
21 17667 164/12 62 F L LIQ 4 DC NEG 7.31 52 2 2 7 13 II DC-II
22 14100 175/12 38 F L UOQ 1 FAD 1.91 10 0 0 3
23 19301 179/12 45 F L UOQ 4.5 DC NEG 7.04 48 2 2 6 10 I DC-II
24 19905 197/12 44 F R LOQ 1 EPI 5.35 41 2 2 5
25 6210 205/12 62 F R UOQ 4 DC NEG 7.67 58 2 2 7 13 II DC-III
26 23655 256/12 23 F L LIQ 1.5 EPI 6.21 51 2 2 5
27 8403 264/12 32 F R LOQ 1.5 FCD 2.17 13 0 0 3
28 8638 276/12 71 F L UOQ 5 DC POS 7.36 52 2 2 7 10 I DC-II
29 24858 278/12 57 F R UOQ 4.5 DC NEG 7.87 54 3 3 7 15 III DC-III
30 9216 289/12 30 F R UOQ 2 EPI 3.82 31 1 1 4
31 8105 298/12 44 F R LOQ 7 DC POS 9.54 71 3 3 8 17 III DC-III
32 8644 313/12 52 F R UOQ 3.5 DC POS 7.31 53 2 2 6 13 II DC-II
33 10163 323/12 56 F L UOQ 2.5 ADH 4.92 42 1 1 4
34 31292 350/12 19 F L UOQ 1.5 EPI 4.65 36 1 1 5
35 31709 361/12 37 F L UIQ 1 FAD 2.33 11 0 0 3
36 11231 365/12 43 F L UOQ 4.5 DC NEG 6.94 47 2 2 6 9 I DC-I
37 11449 384/12 40 F L UOQ 4.5 DC NEG 8.04 59 3 3 7 14 II DC-III
38 35836 404/12 36 F L LOQ 1.5 ADH 4.99 37 1 1 5
39 38464 409/12 33 F R UOQ 1 EPI 4.47 33 1 1 4
40 38602 422/12 23 F L LOQ 1 FAD 2.13 9 0 0 3
41 41510 445/12 56 F L UOQ 4 DC NEG 6.89 49 2 2 6 13 II DC-II
SIZE FNAC DIAGNOSIS
LN 
STATUS
ROBINSON 
SCORE
ROBINSON 
GRADE
HISTOPATH 
DIAGNOSIS
AgNOR SCORE
SL.NO I.P. No FNAC. No AGE SEX SIDE QUADRANT
42 41469 446/12 56 F L LOQ 1.5 DC NEG 5.86 40 2 2 6 7 I DC-I
43 13470 450/12 45 F L UOQ 4 DC POS 7.02 50 2 2 6 13 II DC-II
44 41439 456/12 62 F L UOQ 4 DC NEG 7.17 51 2 2 7 13 II DC-II
45 42414 462/12 55 F R LOQ 1.5 DC NEG 6.14 43 2 2 6 8 I DC-I
46 40338 476/12 18 F L CQ 2 IDP 4.86 39 1 1 4
47 13880 518/12 35 F L LIQ 1.5 FCD 1.74 4 0 0 3
48 48252 542/12 43 F R UOQ 1 EPI 4.14 32 1 1 4
49 50720 557/12 19 F R UOQ 1.5 EPI 4.12 29 1 1 4
50 50982 570/12 38 F L LOQ 1.5 FCD 2.96 23 0 0 3
51 51876 575/12 19 F L UOQ 1 FAD 3.06 21 0 1 3
52 56990 646/12 24 F L UIQ 0.5 FCD 2.36 4 0 0 3
53 58771 669/12 45 F R UOQ 0.5 FCD 2.94 20 0 1 3
54 52642 685/12 42 F L LOQ 1 FCD 3.11 18 1 1 3
55 61177 693/12 50 F L LOQ 5 DC POS 7.9 54 3 3 8 16 III DC-III
56 63402 698/12 42 F L UOQ 1 FCD 1.83 3 0 0 3
57 17333 701/12 60 F R LOQ 5 DC POS 8.14 60 3 3 8 16 III DC-III
58 62682 710/12 17 F L UOQ 1.5 FAD 2.13 9 0 0 3
59 63875 718/12 39 F L LOQ 3.5 DC POS 7.06 49 2 2 6 12 II DC-II
60 65718 741/12 30 F L LOQ 1 FCD 3.18 14 1 1 3
61 22731 745/12 17 F L UOQ 1.5 EPI 3.92 27 1 1 4
62 65894 746/12 42 F R LOQ 4.5 DC POS 7.67 52 2 2 7 12 II DC-III
63 69993 775/12 62 F R UIQ 3.5 DC NEG 7.27 46 2 2 7 10 I DC-II
64 17995 779/12 30 F R UIQ 2 ADH 4.17 29 1 1 4
65 70025 786/12 39 F R LOQ 1.5 ADH 5.16 42 1 1 5
66 50206 794/12 40 F L LOQ 3.5 DC NEG 6 47 2 2 6 12 II DC-II
67 25141 809/12 45 F R LOQ 4 DC NEG 7.61 58 2 2 7 14 II DC-II
68 25223 810/12 42 F R UOQ 2.5 ADH 4.86 33 1 1 4
69 25617 823/12 34 F R UOQ 3.5 DC NEG 7.09 47 2 2 6 13 II DC-II
70 25894 834/12 45 F R UOQ 3.5 DC NEG 5.8 40 2 2 6 8 I DC-I
71 71968 840/12 37 F L LOQ 1 FAD 3.24 25 0 0 3
72 26611 863/12 66 F L CQ 2 IDP 5.83 42 2 1 5
73 73779 871/12 35 F R LIQ 1 FCD 1.67 14 0 0 3
74 71349 879/12 33 F R UOQ 1 EPI 5.97 42 2 2 5
75 76921 902/12 43 F R LIQ 0.5 FAD 3.35 22 1 1 4
76 75008 904/12 20 F L LOQ 0.5 FAD 3.32 23 1 1 3
77 78731 913/12 40 F R LOQ 1 FAD 2.01 6 0 0 3
78 79015 933/12 40 F L UIQ 1.5 ADH 5.23 43 2 2 5
79 82892 992/12 24 F R UOQ 0.5 FAD 2.34 11 0 0 3
80 85138 1026/12 25 F R LOQ 0.5 FAD 1.85 9 0 0 3
81 23237 1027/12 27 F L UOQ 0.5 FAD 2.09 6 0 0 3
82 88430 1054/12 40 F R UOQ 6 DC NEG 8.56 62 3 3 8 14 II DC-III
83 89371 1064/12 25 F L UIQ 0.5 FCD 2.19 10 0 0 3
84 89930 1084/12 70 F L LOQ 4 DC NEG 6.74 47 2 2 7 13 II DC-II
85 93242 1126/12 40 F R UOQ 2 ADH 5.12 38 1 1 5
86 36973 1159/12 44 F L UOQ 5.5 DC NEG 6.18 41 2 2 6 12 II DC-II
87 36931 1162/12 53 F R UOQ 4.5 DC POS 7.28 54 2 2 7 14 II DC-II
88 37791 1204/12 40 F L LOQ 5 DC NEG 6.71 48 2 2 6 13 II DC-II
89 100702 1227/12 35 F R UOQ 1.5 EPI 4.52 33 1 1 5
90 109385 1318/12 48 F L UOQ 3.5 DC NEG 6.14 40 2 2 6 9 I DC-I
91 162046 1390/12 43 F L UOQ 1 FAD 2.51 16 0 0 3
92 163537 1394/12 47 F L LOQ 1 FAD 1.84 7 0 0 3
93 172702 1514/12 34 F R LIQ 1.5 FAD 2.29 8 0 0 3
94 110902 1553/12 34 F L UOQ 1.5 EPI 2.78 19 1 1 4
95 111586 1602/12 35 F R UOQ 1 EPI 3.72 18 1 1 4
96 191355 1721/12 40 F L LOQ 1 FAD 2.09 9 0 0 3
97 191213 1723/12 45 F R UOQ 1.5 EPI 4.67 32 1 1 4
98 191736 1735/12 38 F L UIQ 2 EPI 3.86 24 1 1 4
99 111858 1744/12 28 F R UIQ 1.5 EPI 5.05 40 1 1 5
100 203626 1900/12 22 F R UOQ 2 ADH 5.83 44 2 2 5
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APPENDIX I 
AgNOR STAINING PROCEDURE 
 
METHOD: 
AgNOR staining was performed using a one step silver – colloid technique. 
PREPARATION OF STAINING SOLUTION: 
Solution A: 2% gelatin in 1% formic acid 
Solution B: 50% aqueous silver nitrate solution 
WORKING SOLUTION: 
One part of solution A mixed with two parts of solution B. 
STAINING METHODS: 
• The aspirated material is smeared onto the slides and is fixed immediately 
in 95% ethanol.  
• The slides are then stained subsequently with AgNOR stain. 
• The working solution mixture A & B are layered over the slides and are 
kept in a dark room for a period of 50 – 60 minutes. 
• The silver colloid was then washed off with deionised water. 
• The smears are then dehydrated through alcohol. 
• Cleared in Xylene. 
• Mounted using DPX mounting medium. 
APPENDIX II 
HEMATOXYLIN AND EOSIN STAINING PROCEDURE 
 
1. The aspirated material is smeared onto the slides and is fixed immediately 
in 95% ethanol.  
2. Stain in alum haematoxylin for 7 min 
3. Wash well in running tap water. 
4. Differentiate in acid alcohol for 5 seconds 
5. Wash well in running tap water 
6. Stain in 1% Eosin Y for 3minutes 
7. Wash in running tap water for 5minutes 
8. Dehydrate through graded alcohols 
9. Clear in Xylene. 
10. Mount using DPX mounting medium  
 
John D.Bancroft, Alan Stevens; “Theory and Practice of 
Histological Techniques”, 4th Ed; Churchill Livingstone; 1996 ;104. 
 
 
 
 
APPENDIX III 
“VALUE OF ROBINSON’S SCORING SYSTEM AND AgNOR SCORE 
IN CLASSIFICATION OF PROLIFERATIVE & MALIGNANT 
EPITHELIAL BREAST DISEASES ON FNAC” 
PROFORMA 
FNAC NO:  ________ .    IP/OP. NO. : _______________ . 
PATIENT NAME: _________________________________________________.  
AGE: _______ .    SEX: M / F   UNIT/WARD: ___________________. 
ADDRESS: _______________________________________________________ .  
CLINICAL DIAGNOSIS: ___________________________________________. 
I) PRESENTING COMPLAINTS: ___________________________________ .  
II) PERSONAL HISTORY: _________________________________________. 
III) FAMILY HSITORY: ___________________________________________ . 
 IV) GENERAL EXAMINATION:____________________________________ . 
VI) LOCAL EXAMINATION: _______________________________________ 
__________________________________________________________________. 
VII) FNAC DIAGNOSIS: ___________________________________________. 
VIII) ROBINSON’S SCORE: _______________. 
IX) HPE DIAGNOSIS: _____________________________________________ .  
X) mAgNOR VALUE: ________________. 
XI) pAgNOR VALUE: _______________. 
XII) SAPA SCORE: _________________. 
XIII) AgNOR SIZE VARIATION: _______________. 
XIV) AgNOR DISTRIBUTION: _________________. 
KEY TO MASTER CHART 
ADH    –  Atypical Ductal Hyperplasia 
AgNOR   –  Argyrophilic Nucleolar Organizer Region 
AgNOR Dis  –  AgNOR distribution 
CQ    –  Central quadrant 
DC    –  Ductal carcinoma 
EPI    – Epithelial Hyperplasia 
F   – Female 
FAD    –  Fibroadenosis 
FCD    –  Fibrocystic disease 
IDP    –  Intra Ductal Papilloma 
L    –  Left Side 
LIQ    –  Lower Inner Quadrant 
LN    –  Lymph Node status 
LOQ    –  Lower Outer Quadrant 
m AgNOR   –  Mean AgNOR 
NEG    –  Negative 
pAgNOR   –  Proliferative AgNOR index 
POS    –  Positive 
R    –  Right side 
SAPA   –  Subjective AgNOR Pattern Assessment 
UIQ    –  Upper Inner Quadrant 
UOQ    –  Upper Outer Quadrant 
